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Ac     Antibody 
AcMo     Monoclonal Antibody 
ADAM 17    ADAM metallopeptidase domain 17 
Ag     Antigen 
Ag490 2-cyano-3-(3,4-dihydroxyphenyl)-N-(benzyl)-2-
propenamide 
AICD     Activation-induced cell death 
ARMS    Amplification Refractory Mutation System 
Bak     Bcl-2 homologous antagonist killer 
BaX     Bcl-2-associated protein X 
Bcl-2     B-cell lymphoma-2 
BM     Bone Marrow 
BSA     Bovine Serum Albumine 
BSF     B-cell stimulatory factor 2 
CBM     Cytokine Binding Module 
C1P     Ceramide 1-phosphate 
cDNA     Complementary DNA 
CLPD-NK    Chronic Lymphoproliferative Disorder of NK cells 
CMV     Citomegalovirus 
Ct     Threshold Cycle 
CTL     Cytotoxic T cell 
DAC     Demethylation agent 5-aza-2’-deoxycytidine 
DISC     Death-inducing signaling complex 
EBV     Epstein Barr Virus 
ECL     ChemiLuminescence 
EDTA     Ethylenediaminetetraacetic acid 
ESA     Erytropoietin Stimulating Agents 
F/H     Ficoll/Hipaque 
FACS     Fluorescence Activated Cell Sorting 
FasL     Fas Ligand 
FCS     Fetal Calf Serum 
FITC     Fluorescein isothiocyanate 
FNIII     Fibronectin type 3-like 
GAPDH    Glyceraldehyde 3-phosphate dehydrogenase 
GM-CSF    Granulocyte-Macrophage Colony-Stimulating Factor 
HRP      Horseradish peroxidase 
HTLV     Human T-Lymphotrophic Virus 
Ig     Immunoglobulin 
IL-6     Interleukin-6 
IL-6Rα    Interleukin-6 Receptor alfa 
IL-2     Interleukin-2 
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IL-15     Interleukin-15 
JAK     Janus Kinase 
LGL     Large Granular Lymphocyte 
LGLL     Large Granular Lymphocyte Leukemia 
Mcl-1     Myeloid cell leukemia sequence-1 
mgp130    Membrane gp130 
mIL-6Rα    Membrane IL-6 Receptor alfa 
MHC     Major Histocompatibility Complex 
MSC     Mesenchimal Stem Cell 
MTX     Methotrexate 
MSP     Methylation Specific PCR 
PAGE     Polyacrylamide gel electrophoresis 
PB     Peripheral blood 
PBMC    Peripheral Blood Mononuclear Cell 
PBS     Phosphate Buffered Saline 
PCR     Polimerase Chain Reaction 
PI     Propidium iodide 
PS     Phosphatidylserine 
Pt     Patient 
RA     Rheumatoid Arthritis 
RBC     Red Blood Cell 
RT     Retro Transcriptase 
RT-PCR    Real Time -polymerase chain reaction 
RTK     Receptor tirosine kinase 
S1P     Sphingosine 1-phosphate 
SDS     Sodium Dodecil Solfate 
sgp130    Soluble gp130 
sIL-6Rα    Soluble IL-6 receptor alfa 
SH2     Src Homology 2 
SOCS     Suppressor of cytokine signaling 
STAT3    Signal Transducer And Activator of Transcription 3 
T     Thymidine     
TAD     Trans activation domain 
TCR     T cell receptor 
T-LGLL    T-Large Granular Lymphocyte Leukemia 
U     Uracil 
UNG     Uracil-DNA glycosylase 
VEGF     Vascular Endothelial Growth Factor 





Large granular lymphocyte leukemia (LGLL) is a rare and heterogeneous lymphoproliferative 
disorder characterized by the chronic proliferation of clonal large granular lymphocytes 
(LGLs) with cytotoxic activity. Two subtypes of LGL proliferations are distinguished: the 
most common type (~85% of cases), T-LGL Leukemia (T-LGLL), is sustained by T-cells and 
the rarer type (~15% of cases), Chronic Lymphoproliferative Disorder of Natural Killer cells 
(CLPD-NK), sustained by NK-cells. This PhD will focus on the T-LGL Leukemia. 
The etiology of T-LGLL still remains matter of debate. The main hypothesis suggests an 
antigenic stimulation as initial step activating LGLs, which undergo a clonal expansion then 
maintained by the abnormal release of cytokines (mainly IL-6 and IL-15) and by an 
impairment of the apoptotic machinery due to the activation of several survival pathways. 
The project developed in this PhD was aimed to better define this etiopathogenetic hypothesis 
and to find new therapeutic targets. 
First of all, we have taken into account the JAK/STAT pathway, reported to be deregulated in 
T-LGLL. We focused on STAT3, constitutively activated in LGLs, and its specific inhibitor 
SOCS3, that we found to be down-expressed and unresponsive to IL-6 triggering. The 
pathophysiology of this mechanism is unclear, since we found no methylation in SOCS3 
promoter region; anyway we still hypothesize an epigenetic mechanism, since the use of a 
demethylating agent restored SOCS3 responsiveness. 
We then focused our attention on the main activator of STAT3/SOCS3 axis, IL-6, and we 
observed that it enhances LGL survival through STAT3 phosphorylation. We also provided 
evidence that IL-6 is mainly expressed by LGLs-depleted PBMC population of T-LGLL 
patients characterized by low levels of circulating LGLs (<55%). The involvement of IL-6 in 
leukemic LGL survival was confirmed by the observation that incubation with anti-IL-6 and 
anti-IL-6Rα (IL-6 receptor) induced apoptosis in LGLs, likely related to a reduction of 
STAT3 phosphorylation. 
The next step was the analysis of IL-6 receptor system that is composed of two functionally 
different chains: IL-6Rα and gpl30. Our data suggested that IL-6 acts through a trans-
signaling mechanism in T-LGLL, being IL-6Rα highly detected in patients’ plasma and 
poorly expressed by LGLs. Interestingly, trans-signaling is peculiarly implicated in 
inflammatory disease. 
Among STAT3 target genes, CCL5 is a chemotactic agent reported to be over-expressed in 
LGL leukemia. In our lab we found that its expression is responsive to IL-6 stimulus. Since 
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the BM of patients is frequently infiltrated by LGLs and mesenchymal stromal cells (BM-
MSCs) are reported to be a putative source of IL-6, we studied their role in T-LGLL and 
demonstrated that they promote LGL survival and may trigger CCL5 expression in LGLs, 
through IL-6 release. 
We then focused on IL-15, a T-LGLL key cytokine mainly expressed by T-LGLL patients’ 
dendritic cells (DC), these latter being considered the responsible for LGL activation through 
antigen presentation. We studied IL-15 effects on IL-6 signaling and we found that this 
cytokine promotes the trans-signaling mechanism through an enhanced IL-6 expression by 
patients’ PBMCs and the inhibition of IL-6Rα expression by LGLs.  
Finally, recent data in the literature reported mutational hot spots in SH2 domain of STAT3, 
suggesting that STAT3 constitutive activation may result from these acquired genetic 
mutations. Accordingly, we analyzed whether patients’ LGLs showed any of STAT3 hot spot 
mutations up to now quoted. We observed that two mutations, D661Y and Y640F, were 
detected in nearly 20% of cases and more specifically in patients characterized by a high 





La malattia linfoproliferativa dei linfociti granulati (LGLL) è una malattia rara caratterizzata 
da una linfocitosi cronica dei grandi linfociti granulati (LGL) con attività citotossica. Da un 
punto di vista immunologico, si distinguono due forme di LGLL: La T-LGLL, caratterizzata 
dalla proliferazione di LGL di tipo T, nonché forma più frequente della patologia (~85% dei 
casi) e la NK-CLPD, più rara (~15% dei casi) in cui la linfocitosi viene sostenuta da cellule di 
tipo NK. 
L’eziopatogenesi della T-LGLL risulta essere ancora materia di dibattito. L’ipotesi più 
accreditata indica la stimolazione antigenica come evento in grado di attivare gli LGL; queste 
cellule intraprendono dunque un’espansione clonale, che viene mantenuta in un secondo 
tempo dal consistente rilascio di citochine (prevalentemente IL-6 ed IL-15) e da un equilibrio 
vita/morte cellulare alterato, generato quest’ultimo dalla contemporanea attivazione di 
numerose vie di sopravvivenza cellulare. 
Nel nostro laboratorio abbiamo seguito differenti linee di ricerca, con l’obiettivo di verificare 
tale ipotesi eziopatogenica e trovare nuovi target terapeutici. 
Abbiamo preso prima di tutto in considerazione la via di segnale JAK/STAT, che si riporta 
essere alterata nella T-LGLL. Ci siamo soffermati in particolare sulla proteina STAT3, che 
risulta essere costitutivamente attivata, e su SOCS3, suo specifico inibitore, emerso essere, dai 
nostri studi, down-espresso e non responsivo all’IL-6 nella T-LGLL. 
Le basi fisiologiche determinanti il mancato meccanismo a feed-back negativo di SOCS3 non 
risultano ancora definite, dal momento che il promotore di SOCS3 non è risultato essere 
regolato tramite metilazione; è possibile tuttavia che un meccanismo epigenetico sia 
comunque responsabile dell’alterata regolazione della via di segnale JAK/STAT, in quanto 
abbiamo osservato che l’uso di un agente demetilante è in grado di ripristinare l’attività 
inibitoria di SOCS3. 
Abbiamo quindi analizzato il principale attivatore dell’asse STAT3/SOCS3, ovvero 
l’interleuchina 6 (IL-6), evidenziando come tramite l’attivazione di STAT3 essa sia in grado 
di promuovere la sopravvivenza degli LGL. Abbiamo inoltre rilevato che tale citochina è 
espressa in particolar modo dai PBMC non LGL di pazienti caratterizzati da bassi livelli di 
LGL circolanti (<55%). 
Il coinvolgimento di IL-6 nella sopravvivenza degli LGL è stato confermato da un’induzione 
dell’apoptosi in seguito a coltura con anticorpi bloccanti anti-IL-6 ed anti-IL-6Rα (recettore α 
dell’IL-6), dovuta ad una riduzione dei livelli di STAT3 attivata. 
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Passaggio successivo è stato analizzare il sistema recettoriale di IL-6, composto da due 
differenti catene: IL-6Rα e gpl30. I dati ottenuti suggeriscono un meccanismo di trans-
signaling, particolarmente coinvolto nei processi di tipo infiammatorio, alla base dell’azione 
di IL-6 nella T-LGLL; IL-6Rα è presente infatti ad alti livelli nel plasma dei pazienti, pur 
venendo scarsamente espresso dagli LGL.  
Tra i geni target di STAT3 vi è CLL5, un potente agente chemotattico che si riporta essere 
over-espresso nella T-LGLL; nel nostro laboratorio abbiamo osservato inoltre che la sua 
espressione è responsiva allo stimolo con IL-6. Dal momento che il midollo osseo dei pazienti 
risulta essere frequentemente infiltrato dagli LGL e che le cellule mesenchimali stromali 
(BM-MSCs) risultano essere una presunta fonte di IL-6, abbiamo analizzato il ruolo di queste 
cellule nella T-LGLL e dimostrato che esse sono in grado di promuovere la sopravvivenza 
degli LGL e probabilmente stimolare l’espressione di CCL5 da parte degli LGL, tramite il 
rilascio di IL-6. 
Abbiamo studiato l’interleuchina 15 (IL-15), una citochina chiave della T-LGLL espressa in 
particolar modo dalle cellule dendritiche (DC) dei pazienti, considerate responsabili 
dell’attivazione degli LGL tramite presentazione dell’antigene. 
Abbiamo analizzato gli effetti di IL-15 sul signaling di IL-6 ed abbiamo evidenziato come 
tale citochina sia in grado di promuovere il meccanismo di trans-signaling attraverso 
l’induzione d’espressione di IL-6 nei PBMC dei pazienti e l’inibizione dell’espressione di IL-
6Rα negli LGL. 
Dati recenti di letteratura riportano, infine, hot spot mutazionali nel dominio SH2 di STAT3; è 
stato ipotizzato che la costitutiva attivazione di STAT3 sia dovuta a tali mutazioni, per tale 
motivo abbiamo indagato, nella nostra coorte di pazienti, la presenza delle mutazioni descritte 
finora riportate in letteratura. Abbiamo riscontrato le due mutazioni, D661Y e Y640F, sono 
presenti in circa 20% dei casi e specificamente in pazienti caratterizzati da un’alta percentuale 




1. LARGE GRANULAR LYMPHOCYTES  
Large granular lymphocytes (LGLs) represent approximately 10-15% of peripheral blood 
mononuclear cells in adult and are involved in cell-based cytotoxicity. Normally present in 
peripheral blood with values ranging from 0.2 and 0.4x109 LGL/L (200-400 LGL/mm3), these 
cells have well defined morphology and phenotype1. LGLs are large cells (15-18 µm) with 
abundant cytoplasm containing typical azurophilic granules and reniform or round shaped 
nucleus (Figure 1)2.  
Basing on immunophenotype we can separate two different classes of LGLs, which are: 
Natural Killer cell line (CD3 negative), representing 85% of total LGL population and T cell 
line (CD3 positive), which constitutes the remaining 15% and needs an activation step before 
acquisition of cytotoxic properties3.  
 
 
Figure 1: Peripheral blood large granular lymphocyte. Reniform nucleus and cytoplasmatic azurophilic granules 
are clearly visible. 
Well defined functional characteristics give LGLs a fundamental role in the progression of 
immune response: both T and NK LGLs have cytoplasmatic granules containing perforins and 
granzymes B4, and have therefore a central role in cell-mediated immune response, being able 
to exert a cytotoxic activity.  
NK-LGLs lack of T-Cell Receptor (TCR), show a MHC (Major Histocompatibility Complex) 
-non-restricted cytotoxicity and belong to innate immune system, T-LGLs on the other hand 
show a TCR rearranging during lymphocyte maturation, moreover are able to exert a MHC-
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restricted citotoxicity and belong to adaptive immune system4. T-LGLs therefore represent 
cytotoxic lymphocytes in vivo (CTLs) and are activated by antigen5,6. 
1.1 PROPERTIES AND FUNCTIONS OF T-LGLs 
Thanks to TCR, T lymphocytes can specifically recognize antigens. This receptor is an 
heterodimer of two trans membrane polypeptide chains (chain α and chain β) covalently 
bound by sulphur bridge. The formation of TCR takes place during T-lymphocytes maturation 
process in thymus, after V(D)J recombination of TCR. A small subpopulation of T-
lymphocytes show another TCR, that contains two different polypeptide chains, γ and δ, and 
characterize γδ T-lymphocyte class. Extracellular peptides can be recognized by TCR only if 
presented by MHC; TCR binding causes transition from double positive cells (CD4+ CD8+) 
to two different cell lines: a regulatory cell type, called lymphocytes T helper (Th) CD4+ 
CD8-, that recognizes antigen presented by MHC class II, and CTL CD8+ CD4-, a cytotoxic 
cell line that recognizes antigen presented by MHC class I7. 
Phenotypically, CTLs express CD3, CD8 and CD57 (adhesion molecules shown by 
completely differentiated effector CTLs), while are CD27 and CD28 negative. Effector 
proteins, like granzymes, perforins and NKG2D receptor, are up-regulated in CTLs, while 
homing receptor like CCR7 and CD62L are down regulated6.  
Following activation, CTLs undergo a strong expansion in order to deal with prolonged or 
quantitatively relevant antigenic stimuli. Since they can specifically recognize antigen on the 
surface of infected cells, CTLs have a key role in cell mediated immunity; this interaction 
initiates a chain of events leading to cell lysis, a mechanism also known as “cell mediated 
cytotoxicity”. 
We can identify two major pathways through which LGLs can kill their targets: granule-
mediated pathway and receptor-mediated pathway8. 
Granule-mediated pathway depends on the exocytosis of cytolytic granules, morphologically 
characterizing LGLs, to induce lysis and apoptosis of target cells. Once target is recognized, 
granules are polarized towards the immune synapse where LGLs interact with target and, after 
that, they can release a variety of cytotoxins, such the pore-forming protein perforin and a 
family of serine proteases-granzymes, like granzyme B (GrB)9. Perforin, in addition to 
directly inducing osmotic lysis by forming pores on target cell membrane, is necessary for 
granzyme delivery within target cells8. 
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Granzymes, by their protease activity, potentiate the death of target cells by cleaving and 
activating the effector caspases as well as pro-apoptotic Bcl-2 family members (Figure 2, 
panel A)9.  
The receptor-mediated pathway relies on the engagement and activation of “death receptor”, 
such as Fas (CD95), a member of tumor necrosis factor receptor family, by their ligands 
(FasL or CD95L). Death receptors are universally expressed on several cell types while, the 
corresponding ligands are frequently found on activated CTLs. Receptor-mediated pathway is 
not specific for the immune system and the death receptor-ligand interaction is not MHC-
restricted.  
Instead, LGL-target interaction brings target cells to the proximity of LGL and upon ligation, 
death receptors cluster and induce the formation of death inducing signaling complex (DISC) 
which involves the same signaling molecules induced by granzymes (Figure 2, panel A)9. 
 
 
Figure 2: (A) Receptor- and granules-mediated cytotoxicity, through Fas or granzymes containing granules, 
respectively; (B) AICD (activation-induced cell death) induction within CTL once the immunity activity is 
completed. (C) Leukemic LGLs show resistance to AICD, due to the involvement of other signaling pathways 
that oppose to AICD. 
Together, granule-mediated pathway delivers an instant and potent cytolytic potential, while 
the receptor-mediated pathway acts as a moderate but persistent supply. Both pathways 
contribute to LGL clearance after activation in order to prevent an enhanced activity of these 
cells that may alter the immunity homeostasis. This “death pathway” is termed activation-
induced cell death (AICD): both granule- and receptor-mediated pathways can act on 
activated LGLs through endocellular or extracellular granule leakage which triggers similar 
signaling pathways as in target cells. After activation, LGLs express elevated death receptors, 
making themselves sensitive to the death ligands causing AICD (Figure 2 panel B)9. 
Panel A Panel A Panel B Panel C 
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Thus, the resistance to Fas-mediated apoptosis and, consequently, the failure to undergo 
AICD is the main reason causing abnormal clonal expansion of LGLs with the final result of 
an accumulation of these cells in peripheral blood that remain competent in the long term 
(Figure 2, panel C). It is well assumed that this event represents the hallmark of LGLL 
disorders10. 
2. LARGE GRANULAR LYMPHOCYTE DISORDERS  
LGL disorder is a rare disease characterized by a clonal and chronic proliferation of cytotoxic 
lymphocytes. In the last years, the understanding of natural history, immunophenotype, 
pathophysiology and treatment of this disease has greatly expanded and LGL disorder is now 
recognized as a well-defined clinical entity. Indeed, on 2008 the World Health Organization 
(WHO) classified this disorder as belonging to T- and NK-cell mature neoplasias.  
The classification holds for three categories11: 
 T-cell large granular lymphocytes leukemia (T-LGLL) 
 Aggressive NK-cell leukemia (ANKL) 
 Chronic lymphoproliferative disorder of NK cells (CLPD-NK). 
Two subtypes of LGL proliferations therefore are distinguished: in the first one, LGL clone is 
sustained by T-cells and it is the most common type of LGL proliferation (~85% of cases)3, 
while in the second LGL clone is sustained by NK-cells and it represents ~15% of cases11. 
2.1 T-CELL LARGE GRANULAR LYMPHOCYTE 
LEUKEMIA  
T-LGLL is the most frequent LGL disorder in Western countries3. Is a rare disease of the 
elderly, with a median age at diagnosis of 60 years, however it has been described in all age 
groups, including in the pediatric population. Males and females are affected equally4.  
2.1.1 Clinical presentation  
T-LGLL typically has an indolent clinical behavior with a median survival >10 years. 
Diagnosis generally follows an incidental finding of cytopenia and about a third of patients 
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results asymptomatic. About 60% of patients will become symptomatic during disease 
course3,4. Recurrent infection and fatigue may occur in association with neutropenia and 
anemia. The liver is often involved histologically but may not be enlarged. The presence of 
lymphadenopathy would be considered an uncommon disease manifestation4.  
Diagnosis of LGL leukemia is established by documentation of an increased number of clonal 
LGLs; initially, a circulating LGL count 2x109/L was considered as mandatory (normal 
number of LGLs in the peripheral blood is 0.3x109/L), but now a lower count (range, 0.4-
2x109L) can be compatible with the diagnosis12. 
Eighty-five percent of patients develop neutropenia during the disease course, that is severe 
(0.5 x 109/L)3,4, in 50%. Anemia and thrombocytopenia are less common and observed in 
approximately 50% and 20% of patients, respectively3,4.  
Possible mechanisms for neutropenia found in LGLL include deregulated Fas/FasL-induced 
apoptosis of myeloid cells, immune complex or antibody-mediated neutrophil destruction, 
hypersplenism or direct inhibition of myeloid maturation by cytokines3,4. Which of these 
mechanisms is dominant remains unclear and may vary among patients.  
T-LGLL is associated with a wide spectrum of autoimmune disorders, most of them involving 
connective tissue. In particular, among arthropathies associated with LGLL, rheumatoid 
arthritis (RA) is the most common autoimmune disease, occuring in 25%-35% of patients3,4. 
Other autoimmune disorders, including systemic lupus erythematous and Hashimoto’s 
thyroiditis, can occur in patients with this disorder, but less frequently4. 
2.1.2 Diagnosis 
The disease should be suspected in all patients with an increased number of LGLs in 
peripheral blood and unexplained cytopenias. A careful morphologic examination of LGLs in 
peripheral blood and/or a flow cytometry analysis of mature T-cell immunophenotyping panel 
(including CD3, CD5, CD7, CD8, CD16, CD25, CD56, CD57, TCRαβ and γδ) and TCR gene 
rearrangement are required. Bone marrow trephine biopsy is usually necessary to confirm the 
diagnosis, particularly if patient requires treatment.  
Main features in T-LGLL diagnosis, is an abnormal proliferation of CD8+ T cells and the 
evidence of clonality, established by gene rearrangement studies (Table 1). Indeed, as T cells 
rearrange TCR genes during their normal development, all the cells arising from a malignant, 
transformed T cell will have the same sequence of TCR genes. This can be demonstrated 
either by Southern Blotting or by Polymerase Chain Reaction (PCR) analysis. However, PCR 
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is currently the technique most widely used in clinical setting. Flow cytometry using 
monoclonal antibodies against TCR variable region family gene segments can also aid in the 
establishment of clonality in T-cell disorders. 
Table 1. Algorithm of the diagnosis of T-LGLL: 
 
a
 Moderate to severe or symptomatic cytopenias. b Symptomatic splenomegaly. c Small oligoclonal/clonal 
populations of circulating LGLs of unknown significance are detected in elderly individuals and after organ 
transplantation; bone marrow biopsy can be valuable in this situation; clinical correlation is recommended. 
Abbreviations: PB, peripheral blood; RA, rheumatoid arthritis; TCR, T-cell receptor. 
Diagnosis of T-LGLL therefore requires three criteria3: 
• Cytopenia (neutropenia and/or thrombocytopenia) 
• Evidence of expansion of CD3+CD8+CD57+ T cells 
• Clonal TCR gene rearrangement 
T-LGLL is an heterogeneous disease, with different clinical manifestations; therefore 
treatment standardization is difficult to achieve13. The disease is often asymptomatic and up to 
half of patients may not require therapy. 
In these cases regular follow-up required to establish the disease course and to identify any 
need for treatment4, usually indicated with significant symptomatic anemia (<9g/dL) and/or 
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need for transfusion, severe neutropenia (<0.5 x 109/L), severe thrombocytopenia (<50 x 
109/L), or any combination of these symptoms3. Other indications for treatment include 
recurrent infections and massive splenomegaly14. 
The main treatment involves immunosuppressive therapy rather than chemotherapy. 
Immunosuppressive therapy includes methotrexate (MTX) or cyclophosphamide (both at low 
doses) or cyclosporine A.  
Therapy with low doses per os MTX (10 mg/m2 per week), a drug employed as an effective 
anti-inflammatory and immunosuppressive agent3,15 with the ability to alleviate RA15, 
demonstrated complete clinical remission through normalization of blood counts15 in about 
only 50% of patients with T-LGLL4,16. Short dosing of corticosteroids in addition to MTX 
treatment may help to alleviate B symptoms and improve the blood cell count4 however, 
because of adverse effects, administration of high-dose steroids for more than 1 month is 
usually not recommended.  
Corticosteroids such as prednisone can be used to hasten the clinical response. Alone, this 
compound has been shown to improve neutrophil count but doesn’t result in a long-lasting 
remission3,13, because LGL clone continues to persist. Prophylactic antibiotics therapy is 
recommended for patients under corticosteroids therapy, presenting severe symptomatic 
neutropenia3. 
Administration of growth factors, as ESA (Erytropoietin Stimulating Agents) and GM-CSF 
(Granulocyte-Macrophage Colony-Stimulating Factor), may help to treat cytopenias, even if 
for short periods. 
Treatment with chemotherapic agents should be considered for patients refractory or relapsing 
after immunosuppressive therapy17 and for young individuals with a significative medullary 
infiltration. 
Treatment with purine analogs like Pentostatine, Fludarabine and 2-chlorodeoxyadenosine 
(2CDA) gave promising results, even if in a low percentage of patients10,18,19.  
Monoclonal antibodies like Alemtuzumab (anti-CD52), Humanized MiK-β-1(anti-CD122) 
and Siplizumab (anti-CD2), antithymocyte globulin or splenectomy are considered treatment 
options in the case of failure with the first-line treatment3. 
2.1.3 Etiology 
The etiology of T-LGLL still remains matter of debate, due to the fact that no single, specific 
agent but a series of events can finally trigger LGLs proliferation. Some reports strongly 
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support the role of chronic antigenic stimulation by exogenous antigens, such as human T-cell 
lymphotrophic virus (HTLV) or putative endogenous autoantigens as the initial stimulus 
inducing the activation and clonal expansion of effector CD8+ LGLs4. Later, LGLs expansion 
may be sustained by the action of cytokines, like interleukin-2 (IL-2) and interleukin-15 (IL-
15)2 (Figure 3).  
The exact role of retroviral infection as etiologic agent has not been entirely established4, it 
has been described that most patients with T-LGLL are not infected with prototypical HTLV, 
but they showed serum reactivity against a small peptide derived from the HTLV-I envelope 
protein p21e16. 
 
Figure 3: T-LGLL Etiopathogenetic hypothesis. Abbreviations: IL-2, Interleukin 2; IL-15, Interleukin 15; 
AICD, activation-induced cell death. 
Data from our lab20 have shown a possible role for dendritic cells (DC) in the pathogenesis of 
LGLL. These cells belong to the antigen-presenting cell (APC) family, characterized by the 
ability to recognize antigens and later to present the same antigens and adhesion molecules on 
their surface to T cells, inducing their activation.  
DCs can be involved in LGLs proliferation; after the recognition of a specific antigen they 
may maintain proliferation by releasing cytokines like IL-2, IL-15 and IL-18. 
Immunohistochemical analysis performed on T-LGLL patients osteomedullary biopsies have 
shown the presence of direct contact between LGL and DC, in contrast to healthy controls in 
which cells have a random distribution. It has been hypothesized that the medullary 
environment represents the place where pathological proliferation starts and thus DCs 
represent viral infection target cells20. 
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Moreover, proliferating LGLs are characterized by an impaired apoptotic machinery, due to 
the activation of several survival pathways, which results in LGL aberrant outliving and 
number increase. 
3. CYTOKINES INVOLVED IN T-LGLL 
3.1 INTERLEUKIN 6 
IL-6-type cytokines form a subfamily of helix bundle cytokines. All IL-6-type cytokines 
comprise four long α-helices termed A, B, C and D (Figure 4) which are arranged in a way 
that leads to up-up-down-down topology.  
IL-6 is produced and released by a wide variety of cell types, e.g. monocytes/macrophages, 
fibroblasts, endothelial cells, and astrocytes in response to infections or injuries.  
IL-6 exerts pleiotropic functions by acting in endocrine, paracrine and autocrine manner on 
different target cells. It plays important roles in the regulation of immune system and is the 
main mediator of the acute-phase response which is characterized by the synthesis and 
secretion of acute-phase plasma proteins by the liver, elevated serum glucorticoid levels and 
often fever. It is known that IL-6 leads to the differentiation of both B and T lymphocytes, 
acts as a differentiation factor in hematopoiesis and in general, regulates differentiation, 
proliferation and survival of many other cell types21. 
 
Figure 4: The four domains A, B, C and D, that form á-helices, are highlighted in different colors.  
This cytokine exerts its biological activities through two molecules: a non-signaling α-
receptor termed IL-6 receptor α chain (IL-6Rα), also known as glycoprotein 80 (GP80) or 
CD126 and the signal transducing receptor glycoprotein 130 (gp130), also referred to as IL-
6Rβ or CD130. The ectodomains of the IL-6 receptors contains an array of Fibronectin type 
III (FNIII)-like and Ig-like domains (Figure 5). Each receptor contain at least a cytokine 
binding module (CBM) domain that consists of two FNIII domains. CBM is characterized by 
conserved structural features, such as a WSXWS motif in the C-terminal domain and a 
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distinct pattern of cysteine residues in the N-terminal domain. An Ig-like domain is also 
located N-terminally to the membrane-proximal CBM22. 
To induce cascade signaling, IL-6 first binds to the trans-membrane IL-6Rα (mIL-6Rα), that 
is not determinant for signal transduction having a small cytoplasmic domain. On the contrary 
gp130 has three additional membrane-proximal FNIII domains22 and its cytoplasmic domain 
contains several potential motifs for intracellular signaling, such as YSTV sequence for SHP2 
(Src homology domain-containing protein tyrosine phosphatase-2) recruitment and YXXQ 
motifs (where X is any aminoacid) for STAT activation.  
gp130 does not have any intrinsic kinase domain but, like other cytokine receptors, its 
cytoplasmic domain contains regions for the association with a non-receptor tyrosine kinase, 
like JAK, and can initiate downstream signaling cascades.  
 
Figure 5: Structural organization of IL-6Rα and gp130. Tyrosine residue of gp130 that become phosphorylated 
are indicated (Y). For gp130 the box1 and box2 regions, as well as the dileucine motif (LL) are showed. 
Abbreviations: CBM, cytokine binding module; FNIII, Fibronectin type III; TM, transmembrane; Ig-like, 
immunoglobuline-like. 
Neither IL-6 nor mIL-6Rα alone binds or activates gp130; IL-6 first binds to mIL-6Rα and the 
IL-6/mIL-6Rα complex is able to recruit gp130 receptor and triggers its homodimerization. A 
high affinity functional receptor complex of IL-6, mIL-6Rα and gp130 is formed; this IL-6 
system is called “classical signaling”23 (Figure 6). 
Whereas membrane-bound gp130 (mgp130) is ubiquitously expressed, mIL-6Rα expression is 
restricted mainly to hepatocytes, neutrophils, monocytes and macrophages; anyway, many 
cells not expressing mIL-6Rα are reported to be responsive to IL-6.  
The cytokine has been found to use an alternative pathway to activate target cells lacking 
mIL-6Rα, called trans-signalling23 (Figure 6), which acts through the soluble agonistic form 
of the IL-6Rα (sIL-6Rα), generated by both alternative splicing of mRNA and limited 




Figure 6: Representation of IL-6 classical signaling on the left and IL-6 trans-signaling on the right.  
One important difference between classical and trans-signaling is that classical signaling is 
correlated with anti-inflammatory and regenerative activities, while trans-signaling 
contributes to the pro-inflammatory activities of IL-6, e.g. by controlling leukocyte 
infiltration, inhibition of T-cell apoptosis and Treg differentiation24. 
It has been shown that in chronic inflammatory diseases such as inflammatory bowel disease, 
peritonitis, asthma, RA and in colon cancer, IL-6 trans-signaling is critically involved in the 
maintenance of the disease state, due to the high levels of IL-6 and sIL-6Rα detected.  
Also a soluble form of gp130 (sgp130) has been discovered, which acts as the natural 
inhibitor of IL-6/sIL-6Rα complex and selectively inhibits IL-6 trans-signaling without 
affecting classic signaling25.  
3.2 INTERLEUKIN 15 
IL-15 is an inflammatory cytokine, belonging to a subfamily of four helix cytokines, that 
stimulates T and NK cells activity. There are two isoforms for this 14-15 kDa glycoprotein 
encoded by interleukin 15 gene on chromosome 4: one of 48 aminoacids (IL-15 LSP) that can 
be bounded to cytoplasmatic membrane or secreted, and another one with 21 aminoacids (IL-
15 SSP), which can be nuclear or cytoplasmatic and has a role in cell cycle regulation. 
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Interleukin 15 is constitutively expressed by a large number of cells, among which 
macrophages, dendritic cells, keratinocytes, fibroblasts, but only few cell types, as monocytes 
and dendritic cells, can translate mRNA26. 
Main interleukin 15 functions include26,27: 
- Stimulus of cytotoxic T lymphocytes proliferation 
- NK cells differentiation from hematopoietic progenitors in bone marrow 
- Induction of NK cells activation 
- Promotion of normal B lymphocytes proliferation and activation 
- Activation of CD3+ and CD3- large granular lymphocytes 
- Attraction of neutrophils and monocytes in sites of infection. 
- Regulation of pro-inflammatory cytokines production by macrophages 
- Induction of IL-2 expression by dendritic cells 
Expression of IL-15 and its specific receptor IL-15R is upregulated in many infective, 
inflammatory and immunological diseases, among which T-LGLL. 
The IL-15 specific receptor consists of: 
- a specific subunit, IL-15Rα 
- IL-15Rβ subunit (CD122) founded also in IL-2 receptor 
- Common γ chain (γc) 
In most cases IL-15 binds IL-15Rα with high affinity in the endoplasmatic reticulum and the 
resulting complex is carried on cell surface where, together with IL-15Rβ, it triggers the 
trasductional cascade (Figure 7). 
An uncommon mechanism requires instead the transfer of IL-15Rα on cell surface, where it 
binds secreted IL-15 (Figure 7). Different IL-15Rα isoforms, derived from alternative 
splicing, have been identified, but it’s not clear yet if they have an agonist or antagonist role 




Figure 7: Binding mechanisms of IL-15 and IL-15Rα. 
Once IL-15/IL-15Rα complex is formed, it is exposed on cell surface, where it contacts IL-
15Rβ and common chain γ and allows IL-15 to exert its functions. This mechanism could 
happens through two ways (Figure 8): 
- Trans-presentation: IL-15/IL15Rα complex of a cell, generally monocyte or dendritic cell, 
binds to IL15Rβ/γc of another cell type, like CD8 T lymphocytes and NK cells. From 
recent studies has emerged that this mechanism of IL-15 signaling pathway is the most 
common28,29. 
Cis-presentation: the IL-15/IL-15Rα complex binds to a IL-2/IL-15Rβ/γc complex located on 
the same cell surface. Activation of several signaling pathways, including JAK/STAT and 
RAS/MEK/ERK, follows IL-15 binding to its receptor.  
 




CCL5 (also known as RANTES) is a potent chemotactic agent for memory T lymphocytes 
and monocytes that belongs to the CC chemokine subfamily and is expressed after cellular 
activation in fibroblasts, T cells, monocytes, endothelial cells and certain epithelial cells30. 
This chemokine is reported to be strongly expressed by peripheral blood mononuclear cells of 
LGLL patients, together with other inflammatory cytokines, as MIP-1β, IL-18, IL-6, IL-15 
and to a lesser extent IL-8 and IL-1Ra31.  
This pattern of cytokine up-regulation characterizes LGLL and can be found also in some 
chronic infections or autoimmune diseases, sustaining the hypothesis for which LGLL is 
characterized by a chronic inflammatory background.  
Moreover, literature data report that among various human T-cell lines (those infected with 
HTLV-I) preferentially express CCL5, supporting the etiopathogenic hypothesis of a chronic 
antigenic stimulation by exogenous antigens, and that this expression is mediated in part by a 
transcriptional trans-activator of HTLV-1, Tax, via the activation of Nuclear factor-kB (NF-
kB)30. 
Yang and colleagues described another mechanism of CCL5 production by NF-kB 
activation32: These Authors found that unphosphorylated STAT3 (USTAT3) binds to the NF-
kB dimers p65/p50 in competition with IkB. The USTAT3/NF-kB complex translocates into 
the nucleus, binds to DNA, and activates NF-kB-regulated genes, among which CCL5. 
Therefore, CLL5 over-expression seen in patients’ plasma could be explained by higher 
expression levels of USTAT3 in T-LGLL patients, due to the constitutively activated 
JAK/STAT axis. 
4. SIGNALING PATHWAYS ACTIVATED IN LEUKEMIC 
LGLs 
Signaling cascades serve several purposes: to carry a message from the cell surface into the 
nucleus, to amplify the signal and to regulate the cell in order to adapt to the environment. 
Doing so, signaling pathways do not work isolated, instead they are involved in dynamic and 
complex interactions. 
As mentioned above, while normal activated CTLs readily undergo Fas-FasL-mediated 
apoptosis, leukemic LGLs are resistant to FasL-mediated apoptosis or AICD. This raises from 
two possible causes: (1) Fas-FasL apoptotic machinery is deficient in leukemic LGLs, or (2) 
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some constitutively survival signals keep leukemic LGLs alive despite of Fas-mediated death 
signals. 
Starting from the actual knowledge that no mutations in Fas or FasL genes were found in 
LGLL4, we can consider that some survival signals keep leukemic LGLs away from death. 
There are several intracellular signaling pathways, having a cross-talk with the Fas-FasL 
pathway, that could be responsible for AICD escaping. 
Concerning Fas-FasL pathway alteration, it was reported an abnormal DISC formation; 
indeed, higher basal levels of c-FLIP protein, a DISC inhibitor, were detected that contributes 
to the Fas-resistant phenotype in leukemic LGLs4. 
Many signaling pathways are deregulated in LGL leukemia (Figure 9)9,33,34: 
• RAS/MEK/ERK: a constitutive active form of Ras (H-Ras-GTP) is expressed in PBMCs, 
promoting cell survival by directly inducing transcription of FLIP and myeloid cell leukemia 
sequence-1 (Mcl-1) genes; 
• NF-kB: LGLs show constitutively active NF-ĸB, that induces the expression of Mcl-1 and c-
Rel genes; 
• PI3K/Akt: SFK maintains PI3K in its constitutively activated form, with consequent 
constitutive Erk activity. The result is abnormal DISC formation and Fas-resistance; 
• JAK/STAT: STAT1 and STAT3 are constitutively activated and STAT3 induces the 
expression of Mcl-1 gene; 
• Sphingolipid Rheostat: LGLs express abundant anti-apoptotic sphingosine 1-phosphate 
(S1P) and ceramide 1-phosphate (C1P) and low levels of proapoptotic ceramide and 
sphingosine. 
The signaling network model proposed by Zhang et al34 suggests that the persistence of the 
cytokine IL-15 and platelet-derived growth factor (PDGF) is sufficient to reproduce all known 
deregulations in leukemic T-LGLs.  
IL-15 alters the expression of Bcl-2 family members, i.e. Bcl-2, Bcl-XL, Bim, Noxa, and 
Mcl-1 and many of these genes result deregulated in T-LGLL, such as Bcl-2 related X gene 
(Bax), that is down-regulated, and Mcl-1, which is up-regulated (Figure 9)34. The deregulation 
of T-cell homeostasis due to the alteration of pro- and anti-apoptotic factors could be 
responsible for leukemic LGLs survival. In the present study a particular attention has been 





Figure 9: Various survival signaling pathways interact and cross-regulate each other at various levels. The 
dynamic interaction leads to survival of leukemic large granular lymphocytes.  
4.1 THE JAK/STAT PATHWAY 
JAK/STAT pathway is one of the few pleiotropic cascades used to transduce a multitude of 
signals for cell development and homeostasis. In mammals, JAK/STAT pathway is the 
principal signaling mechanism for a wide array of cytokines and growth factors.  
JAK activation stimulates cell proliferation, differentiation, migration and apoptosis, events 
that are critical to hematopoiesis, immune development, and other processes. Predictably, 
mutations that involve pathway activity affect these processes35, for example, mutations that 
constitutively activate or fail to regulate JAK signaling properly, cause inflammatory disease, 
erythrocytosis and different forms of leukemia.  
Following T-cell activation, the association of two receptor subunits’ cytoplasmic domains 
with JAK tyrosine kinases is required (Figure 10).  
Two kinase-homologous domains at the C-terminus characterize JAK kinases: one is a non-
catalytic regulatory domain, whereas the other has tyrosine kinase activity. 
Once ligand-receptor complex is formed, it triggers its own dimerization and recruits two 
JAKs, which are therefore brought into close proximity; this step allows their trans-
phosphorylation and activation.  
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Once JAK kinases are activated, they phosphorylate both receptors and the main substrates, 
represented by STAT proteins, a family of transcription factors, which in turn can form homo- 
or heterodimers9. These proteins reside as latent transcription factors in the cytoplasm and 
once activated through phosphorylation and dimerization, they translocate into the nucleus 
and induce gene transcription (Figure 10).  
In T-LGLL STAT3 is constitutively activated36,37. The activated form of STAT3 binds to the 
enhancer regions of target genes that are involved in apoptosis and cell proliferation, such as 
Bcl-xl, Mcl-1, IAP family, cell-cycle regulator cyclin D1, c-Myc, and vascular endothelial 
growth factor (VEGF)38. 
 
Figure 10: The IL-6/JAK2/STAT3 pathway. gp130 activation through binding of IL-6/IL-6Rα complex, 
mediates the activation of JAK protein that in turn phosphorylates STAT3. Once STAT3 is activated, it 
dimerizes and translocates into the nucleus to induce transcription of target genes like Mcl-1 and suppressor of 
cytokine signaling 3 (SOCS3).  
The key role of STAT3 target genes requires a refined regulation mechanism, mainly carried 
on by SOCS proteins, a family of at least eight members containing a SH2 domain 
(phosphotyrosine binding), a SOCS box at the C-terminus (ubiquitin ligase binding) and a 
small kinase inhibitory (KI) region located N-terminal to the SH2 domain.  
SOCS proteins complete a negative feedback loop in the JAK/STAT pathway: activated 
STATs stimulate transcription of SOCS genes and resulting SOCS proteins can affect their 
negative regulation by different means in order to turn off the pathway: 
- by binding phosphotyrosines on the receptors, SOCS inhibits the recruitment of signal 
transducers, such as STAT proteins, to the receptor; 




The constitutive expression and activation of STAT1 and STAT3 by leukemic LGLs could be 
responsible of their survival; as a matter of fact, 2-cyano-3-(3,4-dihydroxyphenyl)-N-
(benzyl)-2-propenamide (AG490), an inhibitor of JAK2/3 and consequently of STAT1/3, can 
restore apoptosis and Fas sensitivity in LGLs.  
In our lab we focused our attention on STAT3 protein. This protein contains about 750-850 
amino acids and the domain structure comprises from N- to C-terminus: an oligomerization 
domain, the so-called coiled-coil domain, the DNA-binding domain in the center of the 
molecule, the linker domain, the SH2 domain that binds to a specific phosphotyrosine in a 
cytokine receptor’s cytosolic domain and the trans-activation domain (TAD) with critical 
tyrosine and serine residues (Figure 11).  
Unphosphorylated STAT3 represents the inactive form, that resides in the cytoplasm until 
activation occurs by transient association of STAT3 with cytokine receptors39.  
STAT3 recruitment to the activated JAKs has been shown to be mediated by SH2 domain and 
requires the phosphorylation of receptor tyrosine motifs, specifically tyrosine 70539. The 
phosphorylation activates STAT3, that can form homodimers or heterodimers and translocates 
to the nucleus, where it induces the expression of target genes.  
After cytokine stimulation STAT3 is phosphorylated also on serine residue 727 within the 
trans-activation domain, although it is not clear what is the serine kinase involved in the 
process. Serine residue 727 phosphorylation seems unable to interfere with STAT3 tyrosine 
phosphorylation, while it regulates STAT3 transcriptional activity40. 
STAT3 specific inhibition, which could be performed by antisense oligonucleotides, has been 
shown to induce significant apoptosis and to restore Fas-sensitivity in leukemic LGLs. In 
particular, STAT3 inhibition correlates with a Mcl-1 decrease, indicating a role of this anti-
apoptotic protein in LGLs survival37. 
 
Figure 11: STAT protein structure. Abbreviations: Y, tyrosine; S, serine.  
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Recent data in the literature report mutational hot spots in SH2 domain of STAT3; it has been 
hypothesized that constitutive activation may result from increased stabilization of STAT3 
homodimers or heterodimers through enhanced hydrophobic attraction between STAT 
monomers caused by STAT3 mutations41,42. We therefore analyzed whether patients’ LGLs 







AIM OF THE STUDY 
The PhD project carried on different research lines with the aim to better understand the 
pathogenesis and the molecular mechanisms characterizing the development of T-LGLL. 
T-LGLL is characterized by a chronic and clonal expansion of LGLs, sustained by a 
continuous cytokine stimulus and an impairment in the apoptotic machinery. This latter is due 
to the activation of several survival signaling pathways. 
In our lab we focused on JAK/STAT pathway, since it is reported to be deregulated in T-
LGLL, with a constitutive activation and over-expression of the transcription factor STAT3.  
In order to explain this impairment we studied: 
- SOCS3 expression and promoter region. This protein is STAT3 specific inhibitor, 
normally acting through a negative feedback mechanism. Being among STAT3 target 
genes, it is expected to be, in turn, over-expressed in T-LGLL.  
- IL-6 levels and its receptor system to evaluate its involvement in the development of 
T-LGLL, considering that it is reported to be the main activator of JAK/STAT 
pathway.  
- IL-15 levels and its effects on IL-6 signaling. IL-15, as IL-6, is an inflammatory 
cytokine and has a well defined key role in T-LGLL. It is mainly secreted by patients’ 
cells belonging to the monocyte/macrophage lineage, among which DC, that are 
considered the responsible of LGLs antigen activation. 
- STAT3 mutations in SH2 domain, since in some patients affected by T-LGLL, STAT3 
hot spot mutations, inducing STAT3 activation, have been recently demonstrated. 
Being bone marrow of patients frequently infiltrated by LGLs, we studied also: 
- The role of CLL5 in LGL BM infiltration. CCL5 is induced by STAT3, is a strong 
chemotactic agent and an important mediator of acute and chronic inflammation, and 
is reported to be over-expressed in LGLL. 
- BM-MSCs involvement in the survival maintenance and compartmentalization of 







MATHERIALS AND METHODS 
1. PATIENTS AND CONTROL DONORS 
Sixty patients affected by T-LGLL were studied. Chronic peripheral blood lymphocytosis 
(lasting more than 6 months) was sustained by at least 2,000 LGLs/mm3 (range: 25%-95% of 
lymphocyte pool)43, with the phenotype CD3+CD57+CD8+CD16±CD56±. At the time of the 
study no patients had received treatment, with a follow up ranging from 1 to 16 years. In all 
patients clonality was demonstrated by molecular analysis of TCR gene rearrangement and 
often a prevalent expression of a discrete TCR Vβ region was established, according to the 
methods previously reported44. Twenty healthy donors were used as controls in all 
experiments performed, which were approved by the Institutional Review Board. All enrolled 
patients and controls provided written informed consent in accordance with the Declaration of 
Helsinki. 
2. LYMPHOCYTES SEPARATION FROM PERIPHERAL 
BLOOD 
Lymphocytes were isolated from peripheral blood of T-LGLL patients and healthy 
individuals. Mononuclear cells were obtained from samples of heparinized venous blood by 
Ficoll-Hypaque (F/H) (Amersham Biosciences; San Francisco, CA) density gradient 
centrifugation. 
This is a simple and rapid method of purifying PBMCs that takes advantage of the density 
differences between mononuclear cells and other elements of the blood. Mononuclear cells 
and platelets collect on top of the F/H layer because they have a lower density. In contrast, red 
blood cells (RBC) and granulocytes have a higher density than F/H and collect at the bottom 
of the F/H layer. 
Peripheral blood was first diluted in 1:3 ratio with 0.9% sodium chloride (saline) at room 
temperature, gently agitated, and later layered slowly over F/H solution. We proceeded with a 
centrifugation at 900g for 20 min at 20°C, without brake. The ring of mononuclear cells 
formed at F/H interface was aspirated and subjected to two subsequent washes with saline by 
centrifugation at 400g for 10 minutes at 20°C (Figure 13). The pellet was resuspended in an 





Figure 13: Isolation of mononuclear cells from peripheral blood by stratification on Ficoll/Hipaque. By 
centrifugation on F/H, mononuclear cells were isolated from peripheral blood. Mononuclear cells and platelets 
were concentrated above the layer of F/H because they have lower density; on the contrary, the red blood cells 
(RBC) and granulocytes (PMN) have a higher density than the F/H and collect on the bottom of the tube. RT: 
room temperature. 
3. T-LGLs SORTING AND FLOW CYTOMETRY  
The immunophenotypic analysis on lymphocytes obtained from peripheral blood of T-LGLL 
patients was performed through flow cytometry. This technique allows a multiparametric 
evaluation of antigenic characteristic of single cells by the analysis of visible and fluorescent 
light they emit when flow through a liquid medium. 
The immunophenotyping is based on the identification of surface and intracellular Ag using 
monoclonal antibodies (moAbs) conjugated with fluorochromes. The presence of a certain Ag 
is revealed and used as an indicator of belonging to a cell line and of cell level maturation.  
Target cell population used in this thesis was detected by fluorochromes-conjugated moAbs 
(Becton Dickinson, Sunnyvale, CA, USA) anti-CD3, anti-CD16, anti-CD56, anti-CD57 and 
anti-CD8. 
Analysis was performed by flow cytometer FACSCalibur (Becton Dickinson) and data 
obtained were processed by Macintosh CELL Quest software program (Becton Dickinson). 
For each analysis at least 1x104 events were acquired and analysis was performed overlapping 
samples’ histograms (obtained with different antibodies) with isotypic control (fluorescein 
isothiocyanate (FITC)-conjugated IgG1 antibody) histogram. 
LGLs from patients and CTLs from controls (the putative normal counterpart of pathologic 
LGLs, represented by CD8+CD57+ cells) were obtained by sorting process, based on 
recognition of specific surface antigens. 
An antibody conjugated with FITC fluorochrome was incubated with a mononuclear cells 
quantity between 30 and 125x106 and diluted in phosphate buffered saline (PBS) for 20 
minutes at 4°C. IgG1 FITC-conjugated antibody was used as isotypic control.  
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Antibody treated cells were then subjected to two washes and resuspended in PBS-EDTA 
(Ethylenediaminetetraacetic acid). Antibody conjugated cells were then isolated from total 
cell population by FACSAria cell sorter (BD Biosciences, San Jose CA, USA), with a large 
band-pass filter at 530 nm and Argon laser (488 nm, 100mW) that excited FITC 
fluorochrome. For each analyzed sample 5,000 events/sec had been acquired. 
In order to minimize the possibility of nozzle clogs, the sample had to be put through a 40 
micron cell strainer before sorting. After filtering, the cells should be kept on ice and 
protected from light. To avoid clumps formation, for really sticky cells another filtering step 
before sorting was required. Purity and vitality of obtained cells were then analyzed, and 
resulted always higher than 95%.  
Cells were then employed for total RNA extraction. 
4. T-LGLs PURIFICATION BY IMMUNOMAGNETIC 
BEADS  
Alternatively to sorting technique, especially for low cellularity samples, T-LGLs from 
patients were obtained using magnetic separations over columns (MACS; Miltenyi Biotec, 
Auburn, CA). This technique employs superparamagnetic particles coupled to highly specific 
monoclonal antibodies, in our specific case CD57, which magnetically labels target cell 
population. 
Thanks to their small size, approximately 50 nm, microbeads, which are also biodegradable, 
do not activate cells and do not saturate cell surface epitopes. 
In detail, PBMCs obtained from F/H separation were centrifuged at 300g for 10 minutes; after 
removal of supernatant, pellet was resuspended with purification buffer (PBS 1X, BSA 
(Bovine Serum Albumine) 0.5%, EDTA 2 mM). MACS microbeads were added to cell 
suspension (80 µl buffer and 20 µl of microbeads for 10⁷ cells) and incubation at 4-8 °C was 
performed for 15 minutes. A washing step was performed by adding 1-2 mL of buffer per 107 
cells and after a centrifuge step at 300g for 10 minutes, cells were placed onto specific 
magnetic columns (MACS) placed on a MACS magnetic separator; this amplifies the 
magnetic field by 10,000-fold, therefore inducing a high gradient within the column. 
Magnetically labeled cells were retained within the column, unlabeled cells flown through. 
After a washing step, the column was removed from the magnetic field of the separator, and 
the target cells were eluted from the column, washed with physiologic solution, counted and 
used for experiments. 
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5. CELL CULTURES 
LGLs purified from patients or CTLs from controls were cultured at 2x106 cells/ml in RPMI-
1640 medium (Euroclone) containing L-glutamine (2mM) and HEPES (25mM) (Gibco 
Laboratories, Grand Island, NY, USA) added with FCS (Fetal Calf Serum) at a concentration 
of 0,5%. Penicillin (100 U/ml) and streptomycin (100 µg/ml) (Gibco Laboratories, Grand 
Island, NY, USA) were added to the medium at a concentration of 1%.  
Cells were then incubated at 37°C with humidity and 5% CO2. 
All cell treatments were performed under a laminar flow cabinet (Biohazard). We stimulated 
LGLs and PBMCs from patients with IL-6 (10 ng/ml) and IL-15 (10 ng/ml) (R&D Systems, 
Minneapolis, MN, USA) and we evaluated STAT3, pSTAT3, levels at 24 and 48 hours. 
The effect of IL-6 triggering on LGLs or CTLs culture was studied by incubation with 10 
ng/ml IL-6 to observe STAT3 activation, SOCS3 and CCL5 expression after 1 hour, Mcl-1 
expression up to 6 hours and LGL apoptosis up to 7 days. Except for CCL5 the same analysis 
were performed following 96 hours cells treatment with DAC (5 µM). 
To inhibit STAT3 phosphorylation LGLs were cultured with AG490 (50 µM) (Calbiochem, 
Darmstadt, Germany), a specific inhibitor of Jak2. 
To neutralize IL-6 action, PBMCs were cultured in the presence of a anti-IL-6 or anti-IL-6Rα 
(2 µg/ml) antibodies; a mouse IgG1 antibody was used as a control (2 µg/ml). 
Finally we used IL-6 (10 ng/ml) and IL-15 (10 ng/ml) on CD57- cells from patients and 
PBMCs from controls to observe IL-6 and IL-15 expression at 24 h and 48h, and we use these 
cytokines also on patients’ CD57+ cells and controls’ CTLs to observe IL6Rα expression at 
24h and 48h. 
6. MOLECULAR ANALYSIS 
6.1 TOTAL RNA EXTRACTION 
Total RNA was extracted from peripheral blood T lymphocytes by “Rneasy Mini” kit 
(QIAGEN, Hilden, Germany) according to manufacturer’s instruction. 
Lymphocytes were lysed using a solution containing β-mercaptoethanol and lysis buffer; 70% 
ethanol (usually 350 µl or 600 µl) then was added according to product user manual, and 
samples were transferred to a purification column (supplied by the kit) and then centrifuged at 
10,000 rpm for 15 seconds, followed by elute removal. 
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After the addition of 350µl of RW1 buffer (supplied by the kit), samples were centrifuged 
again at 10,000 rpm for 15 seconds and the elutes were discarded. Then we proceeded with 20 
minutes of incubation with 80µl of a DNase I solution (QIAGEN). After having washed with 
350µl of RW1 buffer, followed by centrifugation at 10,000 rpm for 15 seconds, the collector 
tube was replaced. 500µl of RPE buffer (supplied by the kit) were added, the samples were 
centrifuged at 10,000 rpm for 15 seconds, and the elutes were discarded. Again, 500µl of RPE 
buffer were added and a centrifugation at 15,000g for 2 minutes was carried out. Columns 
were then transferred to 1.5ml tubes, 30µl of H2O- Rnase free (supplied by the kit) were 
added on the membrane, and purification was performed by centrifugation at 10,000 rpm for 1 
minute in order to dissociate the RNA from the membranes and bring it into solution.  
The extracted RNA was then quantified using a spectrophotometer Ultrospec 1100 pro 
(Amersham Biosciences). RNA samples were diluted 1:70, their absorbance (A) at 
wavelengths of 260nm (λ nucleotides) and 280nm (λ proteins) was determined, and 
A260/A280 ratio was calculated. Values less than 2 indicate a protein contamination of RNA 
preparation.  
RNA concentration was finally calculated using the following formula: 
A260 x dilution factor x 40 = RNA concentration in µg/ml. 
The value of 40 corresponds to the concentration of RNA, expressed in µg/ml, when obtained 
A260 is 1. 
6.2 cDNA SYNTHESIS 
The reverse transcription from mRNA to cDNA (complementary DNA) uses a reverse 
transcriptase (RT), which generates a cDNA strand from a template of mRNA. 
In this thesis, total RNA has been used as template and the reaction was performed in the 
presence of an oligo-dT primer, which hybridizes to the poly(A) tail of mRNA. The RT used 
is the Myeloblastoma Avian Virus (AMV) polymerase (Promega, Madison, WI, USA); this 
enzyme has 5'→3' activity (with RNA or DNA as a template) and a 3'→5' RNase H activity, 
which degrades the RNA filament of the double helix DNA-RNA, produced during cDNA 
synthesis. This latter was performed by the “Reverse Trascription System” kit (Promega 
Corporation; Madison, WI). 
The reaction mixture is composed of:  
- 4 µl of 25mM MgCl2 
- 2 µl of 10X RT buffer 
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- 2 µl of the mixture of the 4 deoxynucleosides triphosphates (dNTP mix) 10mM 
- 0.5 µl of an enzyme inhibitor of RNase 40 µg/µl 
- 0.6 µl of AMV RT 25 µg/µl 
- 1 µl of primer Oligo (dT) 0.5 mg/ml 
- 1 µg of RNA 
- RNase-free H2O to final volume of 20 µl 
Before the additon of RT reaction mixture, tubes containing template RNA were placed into a 
pre-heated 70°C heat block for 5 minutes. After this initial step, mixture containing RNA was 
incubated at 42°C for 15 minutes, then placed at 95°C for 5 minutes (to stop the RT reaction) 
and, finally, put on ice for a few minutes. Thus, the cDNA obtained was stored at -80°C or 
used immediately to set up the amplification reaction by means of Real Time -polymerase 
chain reaction (RT-PCR). 
6.3 REAL TIME PCR 
RT-PCR is a technique commonly used in molecular biology to detect the amplification of 
cDNA and therefore RNA expression levels. It’s based on the direct correlation between 
fluorescence emission and cDNA amplification.  
In our lab, each sample was amplified in duplicate and genes of interest were STAT3, IL-6, 
IL-6Rα, IL-15, CCL5, Mcl-1 and gp130 besides the housekeeping gene GAPDH 
(Glyceraldehyde 3-phosphate dehydrogenase), which is expressed constitutively in all cells 
and acts as normalizer. For each gene, RT-PCR was also performed on a negative control. 
The amplification of the genes of interest were obtained using ABI PRISM 7000 sequence 
detection system (Applied Biosystems; Foster City, CA) in a volume of 15µl. For each sample 
a reaction mix was used, made with: 
- 1,5 µl cDNA 
- 4,2 µl H2O without RNAse 
- 0,9 µl primer Forward (Fw) 5 µM (Sigma) 
- 0,9 µl primer Reverse (Rev) 5 µM (Sigma) 
- 7,5 µl SYBR Green PCR Master Mix 2X (Applied Biosystems), which contains Taq 
polymerase, A,C,G,U nucleotides, reaction buffer, magnesium chloride, uracil-N-
glycosylase (UNG) and SYBR Green (Applied Biosystems). 
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The primers used for amplification of gene of interest are reported in Table 2 and were 
designed in our lab, except for STAT3, for which we used the primers as described in Haider 
et al45. 
For the reaction, an initial step at 50°C for 2 minutes is required in order to activate UNG 
enzyme, which breaks down possible contamination derived from previous reactions, that 
show uracil (U) in place of thymidine (T)  
After this step, reaction conditions were: 
- Denaturation at 95°C for 10 minutes 
- Annealing at 60°C for 15 seconds 
- Extension at 72°C for 1 second 
A dissociation curve to distinguish specific from nonspecific amplification was also 
generated. 
Threshold cycle (Ct) was acquired for each sample and starting quantities (Co) of each sample 
were obtained with Ct method, which is based on the following equation: 
Co=2-∆∆Ct 
where ∆Ct represents the difference between target gene Ct and housekeeping gene Ct, and 
∆∆Ct is obtained by subtracting sample ∆Ct from calibrator ∆Ct.  
Calibrator is a sample used as reference which is included in every reaction plate in order to 












For 45 cycles 
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Table 2: Primers sequences for RT-PCR.  
PRIMER SEQUENCE 
IL-6 Fw 5’-GGCACTGGCAGAAAACAACCTG-3’ 
IL-6 Rev 5’-TCACCAGGCAAGTCTCCTCATTGAAT-3’ 
SOCS3 Fw 5’-CAGCTCCAAGAGCGAGTACCA-3’ 
SOCS3 Rev 5’-AGAAGCCGCTCTCCTGCAG-3’ 
STAT3 Fw 5’-AGGAGGAGGCATTCGGAAA-3’ 
STAT3 Rev 5’-AGCGCCTGGGTCAGCTT-3’ 
IL-6Rα Fw 5’-GGCTGAACGGTCAAAGACATTC-3’ 
IL-6Rα Rev 5’-CGTCGTGGATGACACAGTGA-3’ 
gp130 Fw 5’-GTACATGGTACGAATGGCAGCATAC-3’ 
gp130 Rev 5’-TCCTTGAGCAAACTTTGGGGTAG-3’ 
GAPDH Fw 5’-AATGGAAATCCCATCACCATCT-3’ 
GAPDH Rev 5’-CGCCCCACTTGATTTTGG-3’ 
IL-15 Fw 5’-AGTGATGTTCACCCCAGTTGC-3’ 
IL-15 Rev 5’-TGCATCCAGATTCTGTTACATTCCC-3’ 
CCL5 Fw 5’-TCTGCCTCCCCATATTCCTCGG-3’ 
CCL5 Rev 5’-GGCGGTTCTTTCGGGTGACAAAG-3’ 
Mcl-1 Fw 5’-GAAAGTATCACAGACGTTCTCGTAAGG-3’ 
Mcl-1 Rev 5’-AACCCATCCCAGCCTCTTTG-3’ 
 
6.4 DNA EXTRACTION 
Genomic DNA was extracted by “Genomic DNA Purification kit” (Gentra, MN, USA), from 
at least 1x106 to 20x106 PBMCs or CD57+ cells, obtained from peripheral blood. 
According to manufacturer’s instruction, cells were lysed using the Cell Lysis Solution. 
RNAse A solution was added in order to eliminate RNA eventually contained in the sample; 
an incubation at 37°C for 15-60 minutes was then performed. 
Hence RNase A treated cell lysate was cooled to room temperature by placing on ice and 
Precipitation Solution was added. After a centrifugation step the precipitated proteins formed 
a tight pellet. 
The supernatant containing the DNA was poured into a clean tube containing 100% 
isopropanol (2-propanol) and the solution was mixed by inversion in order to facilitate DNA 
precipitation. After a centrifugation step the DNA was visible as a small while pellet. 
Surnatants had to be poured off and 70% Ethanol was added to the tube to wash the DNA 
pellet. 
After a centrifugation step ethanol was poured off and DNA Hydratation Solution was added 
to rehydrate DNA. 
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Rehydrated DNA was then store at 4°C, or at -20°C/-80°C for long-term storage 
Quantification by spectrometer was finally required in order to obtain DNA concentration and 
purity. 
6.5 DNA MODIFICATION AND METHYLATION-SPECIFIC PCR 
(MSP) 
DNA extracted was then modified by sodium bisulfite, converting only unmethylated 
cytosines to uracil, as described by Herman et al46.  
The “Methylamp™ DNA Modification Kit” has been used in order to perform bisulfite 
conversion and converted DNA was used as template for MSP as described47, using either a 
methylation- or unmethylation-specific primer set. 
The sequence amplified was from nucleotides –525 to –384 of the SOCS3 promoter region, 
defining the start codon ATG as +1.  
Methylation- and unmethylation-specific primers are reported in Table 3. 
Table 3: Primers sequences for MSP. 
PRIMER SEQUENCE 
Methylation-specific Fw 5’-GGAGATTTTAGGTTTTCGGAATATTTC-3’ 
Methylation-specific Rev 5’-CCCCCGAAACTACCTAAACGCCG-3’ 
unmethylation-specific Fw 5’-GTTGGAGATTTTAGGTTTTTGGAATATTTT-3’ 
unmethylation-specific Rev 5’-AAACCCCCAAAACTACCTAAACACCA-3’ 
 
PCR products were analyzed in 2% agarose gel stained with Syber Safe (Invitrogen, Paisley, 
UK) and visualized under ultraviolet illumination in order to detect DNA samples containing 
a methylated SOCS3 promoter region. 
6.6 BISULFITE SEQUENCING 
Bisulfite-modified DNA was amplified using primers recognizing SOCS3 promoter region 
from nucleotide –704 to –186 (forward: 5’-GATTTGAGGGGGTTTAGTTTTAAGGA-3’ 
and reverse 5’-CCACTACCCCAAAAACCCTCTCCTAA-3’) as reported by Isomoto et al48.  
The PCR products were cloned into the PCR II vector in accordance with manufacturer’s 
instruction employing the “TOPO-TA cloning kit” (Invitrogen). 
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Plasmid DNA purified from 5 randomly picked clones using the “Plasmid miniprep kit” (Bio-
Rad Laboratories, Hercules, CA) were obtained and prepared for automated DNA sequencing 
analysis. The reaction conditions were as follows: 96°C 10 seconds, 50°C 5 seconds, 60°C 4 
minutes, for 25 cycles.  
DNA was sequenced using dye terminator technology and an ABI 3130 sequencer (Applied 
Biosystems), which is based on Sanger sequencing 
6.7 SCREENING OF SOCS3 AND STAT3 MUTATIONS 
To sequence SOCS3 gene we used primers designed to cover the entire coding region (678 
bp) as reported by Cho-Vega et al.49: 
upstream primer 5'-CATGCCCTTTGCGCCCTT 
downstream primer 5'-AGATCCACGCTGGCTCCGT,  
For the screening of STAT3 mutations D661V, D661Y, D661H, Y640F, N647I and K658N, 
recently described by Koskela et al.41, we constructed the same set of primers to amplify the 
exon 21, where all the mutations are located. Template DNA was obtained from patients’ 
purified LGLs and remaining autologous PBMCs. As healthy control we used DNA obtained 
both from CD8+CD57+ cells and PBMCs of buffy coats.  
DNA was sequenced as described in the previous paragraph. 
The presence of D661Y and Y640F mutations, non-detectable by direct sequencing due to the 
low sensitivity of the method (reaching 25% of positive cells) was also analyzed by a DNA 
tetra-primer amplification refractory mutation system (ARMS) assay, as reported by Jerez et 
al42. 
6.7.1 Sanger Sequencing 
Sanger Sequencing is a multi-step process, consisting of: 
- PCR of STAT3 gene exon 21, located on chromosome 17 
- Control PCR employing an agarose gel at 2% 
- Clonewell based purification/ purification from gel 
- Cycle sequencing, using dye terminator technology 




 Exon 21 PCR 
STAT3 gene exon 21 PCR produces high amounts of exon 21 copies that can be used for 
mutation analysis. For each sample a reaction mix was used, made with: 
- 27.5 µl H2O 
- 5 µl Buffer 10X 
- 3 µl MgCl2 25mM 
- 4 µl dNTPmix 10mM 
- 4 µl Primer Fw 20pM 
- 4 µl Primer Rev 20pM 
- 0,5 µl TaqGold 1U/ul  
Mix were split in aliquots of 48µl that were distributed in PCR test tubes. 2µl of sample’s 
concentrated DNA were then addicted.  
Test tubes were finally centrifugated at 4°C in a mini-centrifuge and put in thermal cycler. 
The reaction conditions were as follows: 
- Denaturation at 94°C for 10 minutes 
- Denaturation at 94°C for 30 seconds 
- Annealing at 60°C for 1minute and 30 seconds 
- Extension at 72°C for 1 minute 
- Extension at 72°C for 10 minute 
- Rapid thermal ramp to 12 °C and hold 
 Control of PCR products employing an agarose gel 
PCR products were analyzed with a 2% agarose gel, addicted of 5% Syber Safe.  
5µl of each sample and 2µl of molecular weight (100 bp) were loaded on gel and 
electrophoretic run was performed. Finally gel analysis and acquisition were performed with 
ChemiDoc (Bio-Rad,USA) strumentation and software. 
 Clonewell based purification 
Exon 21 PCR products were purificated by Clonewell procedure, that requires E-Gel® 
CloneWell™ 0.8% SYBR Safe™ gels (Invitrogen life technologies, California, USA) and the 
For 35 cycles 
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E-Gel® iBase™ Power System (Invitrogen). This system allows the extraction of DNA bands 
of interest from the gel without any additional purification steps. 
 Purification from gel 
Alternatively to Clonewell, purification of Exon 21 PCR products can be performed by 
purification from gel. 
QIAquick Gel Extraction Kit (QIAGEN Duesseldorf, Germany) was used. This protocol is 
designed to extract and purify DNA of 70 bp to 10 kb; up to 400 mg agarose can be processed 
per spin column.  
Once agarose gel was placed on trans illuminator, the band of interest became visible and 
could be excised with a clean, sharp scalpel; the gel slice was putted inside a sterile and 
colorless 1.5 ml tube and weighed. According to manufacturer’s instructions, 3 volumes of 
Buffer QG were added to 1 volume of gel (100 mg ~ 100 µl), followed by incubation at 50°C 
for 10 min (or until the gel slice has completely dissolved). The tube was vortexed every 2–3 
min to help dissolve gel. 
To increase the yield of DNA fragments <500 bp and >4 kb, 1 gel volume of isopropanol was 
added to the sample, and the resulting mix was applied to a QIAquick spin column placed in a 
provided 2 ml collection tube; followed a centrifugation step for 1 minute. 
Flow-through was discarded and QIAquick column was placed back in the same collection 
tube. A wash step was performed adding 750 µl of PE Buffer and performing centrifuge for 1 
minute. 
After flow-through elimination an additional centrifuge was performed for 1 minute. Column 
was the applied to a 1.5 ml collection tube and 30 µl of EB Buffer (10 mM Tris-Cl, pH 8.5) 
were added in the middle of the column. After an incubation of 1 minute at room temperature, 
1 minute centrifuge was performed and column eliminated; the remained tube containing 
purificated DNA sequence was conserved at 4°C. 
 Cycle Sequencing 
Cycle sequencing protocol allows the separation of already purified amplified DNA fragments 
for sequencing process. This method exploits the repetition of heat denaturation, alignment 
and extension cycles, to increase the signal level starting from low DNA template quantities.  
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The technique, based on Sanger sequencing, employs a PCR reaction that synthesizes new 
strands of DNA complementary to a single-stranded template. The template DNA is supplied 
with a mixture of all four deoxynucleotides, four dideoxynucleotides (ddNTPs)-each labeled 
with a different color fluorescent tag, and DNA polymerase. Beacause of this feature, this 
sequencing technique is called dye terminator sequencing. 
Dideoxynucleotides are chain-terminating inhibitors of DNA polymerase; the absence of the 
3'-hydroxyl group (-OH) means that, after being added by a DNA polymerase to a growing 
nucleotide chain, no further nucleotides can be added as no phosphodiester bond can be 
created, leading to the termination of the DNA sequence. 
During PCR, as all four deoxynucleotides are present, chain elongation proceeds until, by 
chance, DNA polymerase inserts a dideoxynucleotide. The result is a new set of DNA chains 
all of different lengths. The fragments are then separated by size using gel electrophoresis. 
As each labeled DNA fragment passes a detector at the bottom of the gel, the color is 
recorded. The DNA sequence is then reconstructed from the pattern of colors representing 
each nucleotide in the sequence. 
Two reaction mix, one with primer Forward (Fw) and one with primer Reverse (Rev), were 
set up for sequencing template forward and reverse strands respectively. Each mix contains: 
- Terminator Ready MIX  8 µl 
- Primer Fw o Primer Rev (3,2pM/ul) 1 µl 
- H2O sterile    8 µl 
Kit ABI PRISM BigDye terminator v1.1 Cycle Sequencing Kits (Applied Biosystems) 
provides both Terminator Ready MIX and Primers.  
Terminator Ready MIX contains: 4 different BigDye Terminator (labeled ddNTPs), DNA 
polymerase AmpliTaq, MgCl2, Tris-HCl Buffer (pH 9.0).  
Employed enzyme is a variant of DNA polymerase Taq; indeed a point mutation is located in 
the active site of the enzyme and determines a less effective discrimination towards ddNTPs.  
Moreover the enzyme has another mutation in the amino terminus domain that apparently 
eliminates the 5’3’ exonuclease activity of AmpliTaq DNA polymerase. 
Two 0.2 ml collection tubes were provided for each samples, one tube for Forward strand and 
the other tube for Reverse strand. In each tube, 9 µl of MIX and 11 µl of diluted sample DNA 
were applied. 
DNA is diluted according to the intensity of bands during CloneWell or gel excision. 
The more visible and therefore concentrated is the band, the less DNA is required; indeed, 
high DNA concentrations interfere with sequencing process.  
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Collection tube with diluted DNA were finally placed in a thermal cycler, set up for the cycle-
sequencing.  
The reaction conditions were as follows: 
- Denaturation at 96°C for 1 minute 
- Denaturation at 96°C per 10 seconds 
- Annealing at 50°C for 5 seconds 
- Extension at 60°C for 4 minutes 
- Rapid thermal ramp to 4 °C and hold until ready to purify. 
 Column purification 
After Cycle Sequencing reaction, fast and easy removal of unincorporated dye terminators 
and primer dimers is performed; therefore reaction products could be analyzed with a DNA 
sequencer.  
The DyeEx 2.0 Spin Kit (QIAGEN) was employed. Spin columns supplied by the kit use gel-
filtration technology.  
To resuspend the resin, the columns were gently vortexed. The caps of the columns were 
losen a quarter turn to avoid a vacuum inside the spin columns. 
The bottom closures of the columns then were snapped off and each column was placed in a 2 
ml collection tube (supplied by the kit). Followed a centrifugation step at 700 x g for 3 
minutes. 
Each spin column was carefully transferred to a 1.5 ml clean centrifuge tube and the 
sequencing reaction was slowly applied directly onto the center of slanted gel bed surface. 
Followed another centrifuge step at 700 x g for 3 minutes, and spin columns were removed 
from the microcentrifuge tubes. The eluates contained the purified DNA, ready for the 
sequencer.  
 Sanger Sequencing 
Sanger sequencing is the first automated method of DNA sequencing based on the selective 
incorporation of chain-terminating ddNTPs by DNA polymerase during in vitro DNA 
replication. The method produces a DNA “ladder” of fragments that differ in length by one 
base and bear a specific ddNTP chain terminator, each of which emit light at different 
wavelengths.  
For 25 cycles 
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Starting from low quantities of DNA, the method can sequence DNA fragments 400-1,000 bp 
long, sorting fragment by length and detecting the fluorescence signal. 
Cycle Sequencing reaction products were loaded in the sequencer ABI PRISM 3130 Genetic 
Analyzer (Applied Biosystems), by following these steps: 
- 0.5 ml capless tubes were labeled with numbers assigned and 25 µl of TSR (template 
suppression reagent) were added to each DNA sample. Tubes were vortexed and pulsed 
down briefly. 
- Samples were placed in the thermocycler at 95°C for 2 minutes to obtain DNA 
denaturation, then were placed immediately on ice until their use. 
 
TSR is used to prevent clogging of the capillary with DNA template during injection.  
The sequencer employs a 16-capillary electrophoresis and is provided with a laser that allows 
multiple colour detection of laser-induced fluorescence. 
Samples were applied in capillaries filled with a polymer (POP7, Applied Biosystems) and 
after an electrophoretic run they are separated according to their molecular weight.   
Light emitted by labeled ddNTPs is collected and, according to wavelenght, separated by a 
spectrophotometer. Obtained data were analyzed by “sequencing analysis” software, which 
elaborates fluorescence signals collected by the sequencer and creates electropherograms.  
6.7.2 ARMS-PCR 
The amplification-refractory mutation system (ARMS) is a simple method for detecting any 
mutation involving single base changes or small deletions. ARMS is based on the use of 
sequence-specific PCR primers that allow amplification of test DNA only when the target 
allele is contained within the sample. The method allows the identification of sequencing 
refractory mutations, which are mutations “invisible” at Sanger sequencing analysis. 
In our lab we performed tetra-primer ARMS-PCR for the detection of D661Y and Y640F 
mutations, reported to be the more frequent mutations in T-LGLL. 
Two PCR reaction tubes containing the same DNA sample were respectively added with 
primers designed for the amplification of mutated DNA in one reaction tube and for the 
amplification of non mutated DNA in the other reaction tube. 
DNA dilution was requested before PCR in order to obtain the final DNA concentration of 
100 ng/µl. Finally, different reaction mix were set up for each mutation of interest (Table 4), 
and reaction conditions were optimized. 
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Table 4: Reagents’ quantities in each ARMS-PCR mix. 
 Mix for D661Y wt Mix for D66Y 
mut 
Mix for Y640F wt Mix for Y640F mut 
Sterile H20 11.5 µl 12.75 µl 11.5 µl 12.75 µl 
10X Buffer 2.5 µl 2.5 µl 2.5 µl 2.5 µl 
MgCl2 25 mM 1.5 µl 1.5 µl 1.5 µl 1.5 µl 
dNTPs mix 10 mM 2 µl 2 µl 2 µl 2 µl 
Fw outer 2.5 µl 2.5 µl 2.5 µl 2.5 µl 
Rev outer 2.5 µl - 2.5 µl - 
Fw inner 1.25 µl - 1.25 µl - 
Rev inner - 2.5 µl - 2.5 µl 
TaqGold 1U/µl 0.25 µl 0.25 µl 0.25 µl 0.25 µl 
24 µl of each mix and 1 µl of diluted DNA were added to sterile reaction tubes to obtain a 
final volume of 25 µl. After a brief pulse down, samples are loaded in the thermocycler. 
Polymerization programs differ, according to searched mutations, for the annealing 
temperature, which depends on nucleotide composition and on primers length (Table 5). 
Thermocycler amplification programs were the following: 
D661Y: 
- Denaturation at 95°C for 5 minutes 
- Denaturation at 94°C for 30 seconds 
- Annealing at 58°C for 30 seconds 
- Extension at 72°C for 1 minute 
- Extension at 72°C for 10 minutes 
- Rapid thermal ramp to 4 °C and hold 
Y640F: 
- Denaturation at 95°C for 5 minutes 
- Denaturation at 94°C for 30 seconds 
- Annealing at 58°C for 30 seconds 
- Extension at 72°C for 1 minute 
- Extension at 72°C for 10 minutes 
- Rapid thermal ramp to 4 °C and hold 
Amplifications products then were loaded on an 3% w/v agarose gel with 5% v/v Syber Safe. 
Electrophoretic run was performed at a gel length dependent voltage for 1 hour and a half. 2 
µl of molecular weight (Invitrogen, Life Technologies) were employed.  
Gel imaging and analysis then were performed with ChemiDoc XRS (Bio-Rad). 
 
For 35 cycles 
For 35 cycles 
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Table 5: Primers sequences for D661Y and Y640F mutations’ ARMS-PCR 
Tetra-primer ARMS PCR uses in a single PCR reaction four primers, one pair of inner allele-
specific primers and one pair of outer standard primers. 
While the forward and reverse outer standard primers bind the DNA template at 3’- and 5’- 
terminal, the forward and reverse inner primers selectively bind the wild-type and the mutant 
allele, respectively.  
The specificity of inner primers is conferred by the identity of the terminal 3’ nucleotide with 
either the wild-type or the mutant allele, and is increased by the introduction of a deliberate 
mismatch at position -1 from the 3’-terminus. 
Reverse inner primer can bind the template only when mutation occurs, while forward inner 
primer binds only to wild type sequence; so, when the mutation occurs, a percentage of 
forward outer primer in employed by PCR reaction with reverse inner primer, while when 
template shows the wild type sequence, a percentage of inner outer primer is employed in 
concert with forward inner primers. Tetra-primer PCR therefore produce not only amplicons 
with outer primers, but also mutation-specific amplicons. 
By positioning the two outer primers at different distances from the polymorphic nucleotide, 
the PCR products differ in length (Table 6), allowing them to be discriminated by gel 
electrophoresis. 
Table 6: Primers combinations and amplicons length for D661Y and Y640F tetra-primer ARMS-PCR. 
 MUTATION  SEQUENCE PRIMERS AMPLICON LENGHT 
 D661Y  Wt/mut Fw outer D661Y + Rev outer D661Y  290bp 
   wt Fw inner D661Y + Rev outer D661Y 182bp 
   mut Rev inner D661Y + Fw outer D661Y 161bp 
 Y640F  Wt/mut Fw outer Y640F + Rev outer Y640F 197bp 
   wt Fw inner Y640F + Rev outer Y640F 119bp 
   mut Rev inner Y640F + Fw outer Y640F 131bp 
PRIMER SEQUENCE 
Primer D661Y Fw outer 5’-CCTAGCTGTAGGTTCCATGATCTTTCCT-3’ 
Primer D661Y Rev outer 5’-AAAATTAAATGCCAGGAACATGGAAAAT-3’ 
Primer D661Y Fw inner 5’-AAATCATCATGGGCTATAAGATCACGG-3’ 
Primer D661Y Rev inner 5’-GGAGACACCAGGATATTGGTAGCGTA-3’ 
Primer Y640F Fw outer 5’-AAAAAATGGGCAGTTTCTCTGAGATGACC-3’ 
Primer Y640F Rev outer 5’-CCAGTGGAGACACCAGGATATTGGTAGC-3’ 
Primer Y640F Fw inner 5’-ACCCAGATCCAGTCCGTGGAACCTTA-3’ 
Primer Y640F Rev inner 5’-ACATGTTGTTCAGCTGCTGCTTTGAGA-3’ 
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7. PROTEIC ANALYSIS (WESTERN BLOT) 
7.1 PREPARATION OF CELL LYSATES 
For each sample aliquots of 250,000 and 500,000 LGLs or PBMCs from patients and CTLs 
from controls were lysed in 50µl of the following buffer: 
- 50mM Tris (hydroxymethyl) aminomethane hydrochloride (Tris-HCl) pH 6.8; 
- 5mM Ethylenediaminetetraacetic acid (EDTA); 
- 10% glycerol; 
- 2% SDS (sodium dodecyl sulphate); 
- 1% β-mercaptoethanol; 
- Dye (Bromophenol blue or pyronin) (Sigma-Aldrich; Milan, IT). 
Subsequently, the lysates were vortex, boiled at of 100°C for 5 minutes and then subjected to 
SDS-PAGE (polyacrylamide gel electrophoresis). 
7.2 POLYACRYLAMIDE GEL ELECTROPHORESIS IN SDS (SDS-
PAGE) 
The polyacrylamide gel electrophoresis in SDS is one of the methods used to separate a 
mixture of proteins on the basis of their molecular weight.  
SDS is a ionic detergent that binds tightly to proteins causing their denaturation; in the 
presence of an excess of SDS, approximately 1.4 g of detergent will bind to each gram of 
protein, providing a constant amount of negative charge per unit mass. Therefore, during 
electrophoresis, all protein-SDS complexes move toward the anode, and thanks to the 
molecular sieve properties of the gel, their mobility is inversely proportional to their 
molecular weight. By the migration of standard proteins of known molecular weight 
simultaneously to samples, it is possible to determine the protein sample weights. 
SDS polyacrylamide gel was prepared following Laemmli method, for which the 
electrophoretic plate consists of two types of gel: 
- Stacking gel at pH 6.8, which concentrates the protein samples so that they are all aligned at 
the start of electrophoresis;  
- Running gel at pH 8.8, in which the real separation of proteins occurs.  
The plate size of 10×8 cm was fixed in the Hoefer Mighty Small-If 250 Scientific Instruments 
machine (Amersham Biosciences). The electrophoresis was run for about 2 hours at 25mA. 
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7.3 WESTERN BLOTTING 
The western blotting (WB) or immunoblotting is an immunoassay able to detect traces of a 
specific protein in a heterogeneous mixture, combining the high resolving power of gel 
electrophoresis with the specificity of the antibodies. The WB is a technique with high 
sensitivity, able to detect quantities of protein in the order of nanogram. 
After SDS-PAGE, proteins were transferred onto a nitrocellulose membrane by the action of 
an electric field, obtained by applying the appropriate current of 350 mA for 2 hours and 30 
minutes. The buffer used for the transfer consisted of: 25 mM Tris, 192 mM glycine, 20% 
methanol and 0.1% SDS with a final pH of 8.0 (Buffer A). After the transfer, the membrane 
was left overnight in the saturation buffer consisting of 50mM Tris-HCl, pH 7.5, 150mM 
NaCl and 5% bovine serum albumin (BSA) (BufferB), for nonspecific sites saturation. This 
step was followed by incubation for 2 hours and 30 min at room temperature of the primary 
antibodies (Abs), diluted in: 50mM Tris-HCl, pH 7.5, 150mM NaCl, 1% BSA (buffer C). 
For our study we used the following Abs: rabbit monoclonal anti-P-STAT3 Tyr XP (Cell 
Signaling; Beverly, Massachusetts); rabbit monoclonal anti-total STAT3 (Cell Signaling; 
Beverly, Massachusetts); anti Mcl-1 (Cell Signaling Beverly, Massachusetts), rabbit 
monoclonal anti-P-ERK (Cell Signaling; Beverly, Massachusetts), rabbit monoclonal anti-
total ERK (Cell Signaling; Beverly, Massachusetts), monoclonal mouse anti-SOCS3 Ab 
(AbD Serotec Oxford, UK) and mouse monoclonal anti-β-actin (Sigma-Aldrich; Milan, Italy). 
Three washes of 10 min, each at room temperature, were subsequently performed, using 
buffer C supplemented with 0.1% Tween. Membranes were then incubated for 30 minutes 
with a secondary anti-IgG Ab, obtained against the animal species immunized for the primary 
Ab. The secondary Ab is conjugated with horseradish peroxidase (Amersham International 
Biotechnology; Buckingamshire, UK) and diluted in buffer C. 
After three additional washes, the membrane was subjected to the detection antibody with the 
enhanced ChemiLuminescence system (ECL) (Pierce; Rockford, Illinois): the membrane is 
incubated for 1 min with 1ml of luminol and 1 ml of H2O2, which in contact with the 
peroxidase and, as a result, with the Ag-Ab complex, gives rise to an oxidation reaction with 
light emission. The blots were acquired with ImageQuant LAS 500 imager (Amersham 
Biosciences) and densitometry analysis was performed with the software ImageQuantTL 
(Amersham Biosciences), provided with the instrument. Quantization on target protein/β-
actin, expressed as arbitrary units, were normalized on Jurkat cell line. 
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8. ELISA TEST  
Enzyme-linked immunosorbent assay (ELISA) is a test that uses antibodies and color change 
to quantify the protein concentration in organic liquids. We used Instant ELISA® 
(eBioscience) for the analysis of IL-6, sIL-6Rα and CLL5 concentration in cells cultures 
plasma and supernatant. 
Samples were stored frozen at -20°C to avoid loss of bioactive human IL-6/sIL-6Rα/CCL5. 
Before starting the number of microwell strips required to test were determined counting the 
desired number of samples plus microwell strips for blanks and standards (coloured). As 
suggested by test protocol, each sample, standard, blank and control sample should be assayed 
in duplicate.  
Protocol is reported in user manual attached to test kit. As general principles an anti-human 
coating antibody is adsorbed onto microwells and the human antigen of interest present in the 
sample or standard binds to antibodies adsorbed to the microwells. Then a biotin-conjugated 
anti-antibody is added and binds to the human protein of interest captured by the first 
antibody. As final step, streptavidin-HRP (Horseradish peroxidase) is added and binds to the 
biotin conjugated anti-human antibody. 
Unbound biotin conjugated anti-human IL-6/ sIL-6Rα/ CCL5 and Streptavidin-HRP is 
removed during a wash step, and substrate solution reactive with HRP is added to the wells. A 
coloured product is formed in proportion to the amount of soluble human protein present in 
the sample. The reaction is terminated by addition of acid and absorbance is measured at 450 
nm. A standard curve is prepared from 7 human IL-6/ sIL-6Rα/ CCL5 standard dilutions and 
sample concentration determined. 
9. APOPTOSIS ANALYSIS BY FLOW CYTOMETRY 
Apoptosis was assessed by annexin V/Propidium Iodide (PI) staining (BD Pharmingen).  
Annexin V/PI staining was performed on PBMCs or LGLs after culture in RPMI 0.5% FCS, 
with or without the following agents: human recombinant IL-6, anti-IL6, anti-IL-6Rα 
antibodies (R&D Systems, Minneapolis, MN) demethylating agent 5-aza-2’-deoxycytidine 
(DAC) (Sigma Aldrich St. Louis, MO) and AG490 ( Calbiochem, Darmstadt, Germany). A 
staining with anti-CD57-FITC was used to identify leukemic LGLs from PBMCs. 
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During the early stages of apoptosis the plasma membrane undergoes profound changes: 
phosphatidylserine (PS), a negatively charged aminofosfolipide normally expressed only on 
the inner side of the plasma membrane, is exposed on the outer surface. Annexin V is a 
protein that, in presence of high concentrations of Ca2+, recognizes and binds selectively the 
PS, and therefore is useful for the identification of apoptotic cells that expose the 
phospholipid on their surface.  
Aliquots of 2x105 cells were harvested, washed, and incubated for 10 min in the dark at room 
temperature with: 100µl of binding buffer, a Ca2+-rich solution that optimizes the binding of 
Annexin V to the PS, 5µl of Annexin V-FITC, and 10µl of PI, provided by the kit (1µl/ml 
final concentration). 
After the incubation, 100µl of binding buffer were added and cells, at the final concentration 
of 1×106cells/ml, were analyzed by flow cytometer FACScan. For each sample 20,000 events 
were acquired and the number of apoptotic cells was expressed as percentage of Annexin V 
positive cells in the total cells analyzed.  
10. CHEMOTAXIS ANALYSIS BY FLOW CYTOMETRY 
Neoplastic LGL motility in presence/absence of MSC conditioned medium, was analyzed by 
adding complete medium and MSC conditioned medium to a multiple well plate, step 
followed by application of Transwell inserts (Corning, NY, USA) and by the addiction of 
complete medium and 2x106/ml cells to their inside compartment (Figure 14). 
Employed medium volumes consider the transwell insert diameter and are suggested by 
manufacturer’s instructions. After 24 hours of incubation at 37°C and 5% CO2, transwell 
inserts were remowed from the multiple well plate, and media from the lower wells were 
transferred into FACS tubes.  
Software CellQuest Pro (BD Biosciences) was used for the analysis and for the set up of the 
instrument. For chemotaxis analysis of collected media we set the acquisition time at 60 
seconds. Each sample was read three times. 
Known the suspension volume drawn by the cytometer and number of acquired events, total 
number of migrated cells could be easily determined. This value in normalized on the number 
of cells migrated in alone condition (well containing only complete medium and not MSC 
conditioned stimulus) and Migration Index (MI) was obtained. 




Figure 14: representative model of chemotaxis analysis. 
11. STATISTICAL ANALYSIS  
Data are expressed as mean plus or minus standard error (SE), and statistical analysis was 






1. LEUKEMIC LGLs DISPLAY HIGH EXPRESSION AND 
ACTIVATION OF STAT3 
According to previously published data37, RT-PCR results showed that STAT3 is over-
expressed in purified leukemic T-LGLs as compared to normal CTLs, that are considered the 
normal counterpart of LGLs in healthy individuals (mRNA arbitrary units: 1.16 ± 0.12 and 
0.65 ± 0.18 respectively, P=.0028) (Figure 15 A). Moreover, by purifying specific LGL 
subsets, we observed that the highest expression of STAT3 was specifically detected on 
CD3+CD57+ clonal LGLs, while autologous LGL-depleted PBMCs were consistently shown 
to display significantly lower amounts of STAT3 both by RT-PCR and by Western blot 
analysis (Figure 15 B, mRNA arbitrary units: 1.33 ± 0.11 and 0.99 ± 0.10 respectively, n = 
10, P<.05; Figure 15 C, Western blot arbitrary densitometry: 1.14 ± 0.12 in patients and 0.45 
± 0.10 in controls, P=.014). Moreover, since STAT3 phosphorylation in tyrosine residue 
confers the ability to STAT3 to induce the transcription of several anti-apoptotic genes, we 
analyzed tyrosine 705 phosphorylation status of STAT3 in patients’ LGLs as compared to 
controls. We observed that leukemic LGLs showed increased, although variable, amounts of 




Figure 15: (A) STAT3 mRNA expression levels in LGLs from patients and in CTLs from controls. Gene 
expression data are normalized to the expression levels of the housekeeping gene GAPDH. (B) STAT3 mRNA 
expression levels in LGLs from patients and in patients’ LGLs depleted PBMC population. Gene expression data 
are normalized to the expression levels of the housekeeping gene GAPDH. (C) Western blotting results of P-
Y705 STAT3 and total STAT3 in PBMC from patients, PBMCs from controls, patients’ LGLs and PBMC 
depleted population. The housekeeping β-Actin was used as calibrator. 
2. SOCS3 IS DOWN-EXPRESSED AND UNRESPONSIVE IN 
PATHOLOGIC LGLS 
STAT3 phosphorylation in tyrosine residue confers the ability to STAT3 to induce the 
transcription of several anti-apoptotic genes and of its specific suppressor, SOCS3.  
Although STAT3 was highly expressed and activated, using RT-PCR we surprisingly 
observed that SOCS3 mRNA median value was significantly lower, almost undetectable, in 
patients’ LGLs as compared with controls’ CTLs (Figure 16 A, mRNA arbitrary units: 0.26 ± 
0.04 and 0.63 ± 0.17 respectively, P=.003; Figure 16 B, Western blot: 0.59 ± 0.05 and 0.85 ± 










Figure 17: (A) SOCS3 mRNA expression levels in patients’ LGLs and LGLs depleted PBMC population. Gene 
expression data are normalized to the expression levels of the housekeeping gene GAPDH; (B) patients’ LGLs 
and LGLs depleted PBMC population are analyzed by Western Blot. Proteins examined are SOCS3 and the 
housekeeping β-Actin. This latter is used as normalizator. 
To evaluate whether, in patients, SOCS3 is responsive to STAT3 phosphorylation, we 
stimulated in vitro both patients’ LGLs and controls’ CTLs with IL-6. This latter is 
considered the main activator of STAT3/SOCS3 axis and its role in STAT3 up-regulation is 
well known50.  
By Western blot and RT-PCR analysis, we observed that, while STAT3 is physiologically 
able to respond to the IL-6 trigger both in patients and controls, SOCS3 expression markedly 
increased only in healthy individuals, whereas in patients’ LGLs it remained quantitatively 
unchanged at near undetectable levels (Figure 18 A; mRNA arbitrary units: 1 hour alone 
condition, 0.12 ± 0.04 in patients’ LGLs and 0.31 ± 0.08 in controls’ CTLs; 1 hour IL-6 
stimulus, 0.16 ± 0.04 in patients’ LGLs and 1.40 ± 0.38 in controls’ CTLs; Figure 18 B, 








Figure 18: (A) SOCS3 mRNA expression levels in LGLs from patients and CTLs from controls at 1 hour, with 
or without IL-6 stimulus. Gene expression data are normalized to the expression levels of the housekeeping gene 
GAPDH; (B) after 1 hour IL-6 stimulus, LGLs from patients and CTLs from controls are analyzed by Western 
Blot. Proteins examined are SOCS3 and the housekeeping β-Actin. This latter is used as normalizator. 
To determine whether SOCS3 gene mutation was present, the SOCS3 coding region was 
sequenced and neither mutation nor alternative splicing of the SOCS3 gene were detected in 
any of the 27 patients studied. 
3. THE DEMETHYLATING AGENT 5-AZA-2’-
DEOXYCYTIDINE (DAC) RESTORES IL-6 MEDIATED 
SOCS3 EXPRESSION IN LGLs FROM PATIENTS 
In several tumors where JAK/STAT pathway is involved, SOCS3 was occasionally found 
silenced through an epigenetic mechanism47,48,51,52. To evaluate whether an epigenetic 
mechanism accounts for SOCS3 inhibition, leukemic LGLs were incubated with DAC, a 
hypomethylating agent that hypomethylates DNA by inhibiting DNA methyltransferase. 
Following 96 hours incubation with this agent, IL-6 treated LGLs showed an increase of 
SOCS3 expression both at transcription and protein level (Figures 19 A-B), progressively 









Figure 19: Results obtained by LGL cultures treated for 96 hours with or without DAC and then stimulated with 
IL-6 for one hour. (A) SOCS3 expression level in LGLs obtained by RT-PCR and normalized on GAPDH. The 
results of four representative patients are reported. (B) Western blot analysis of LGL extracts for phosphorylated 
STAT3, total STAT3 and SOCS3, β-Actin served as a loading control. Two representative cases of patients are 
shown.  
4. SOCS3 RESTORATION LEADS TO P-STAT3 AND Mcl-1 
REDUCTION AND LGL APOPTOSIS 
To investigate whether in leukemic LGLs JAK/STAT signaling was re-established as a 
consequence of SOCS3 restoration, we tested the modulation of P-STAT3 and Mcl-1 after 1, 
3 and 6 hours LGL culture.  
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We observed that SOCS3, once re-established by DAC and triggered by IL-6, led to a 
decrease of P-STAT3 already after one hour (Figure 19 B) and to a progressive decrease of 
Mcl-1, one of the most important pro-apoptotic target genes induced by P-STAT3 in LGLL 
(Figure 20 A-B). 
On the other hand, cells not pre-treated with DAC maintained stable or even increased Mcl-1 
levels. These data were observed both at mRNA and protein level. 
Moreover, in these experiments, we showed that LGL apoptosis increased after DAC 
incubation with a pattern consistent to the addition in the culture of the inhibitor of STAT3 
signaling AG490 (Figure 20 C). 
 
 
Figure 20: Results obtained by LGL cultures treated for 96 hours with or without DAC and then stimulated with 
IL-6 for one hour. (A) Mcl-1 expression level obtained by RT-PCR and (B) by Western blot analysis of LGLs 
from one representative LGLL patient. (C) Annexin V/PI assay measuring LGL mortality percentage (± SE) in 
PBMC culture after DAC treatment (4 days of incubation) or with AG490, inhibiting STAT3 signaling. A 
staining with anti-CD57-FITC was used to identify leukemic LGLs from PBMCs.  
5. METHYLATION ANALYSIS OF SOCS3 PROMOTER IN 
LEUKEMIC LGLs 
To determine whether methylation of SOCS3 promoter was involved in its expression in 
leukemic LGLs, methylation specific PCR (MSP) of SOCS3 promoter was performed using 
genomic DNA isolated from leukemic LGLs and autologous LGL-depleted populations. Once 





promoter sequence, a total of 20 samples from patients and additional 6 samples from healthy 
individuals were analyzed using MSP of the SOCS3 promoter region, comprising nucleotides 
-525 to -384.  
PCR product from LGLs of patients under study identified only unmethylated sequences in all 
cases studied. Consistent results were obtained also from the autologous LGL-depleted 
PBMCs population and in control CTLs. Data on two representative patients are shown in 
Figure 21 A. 
These results were confirmed by sequencing assays on 10 patients and 5 controls (Figure 21 
B). A total of 44 CpG sites located between nucleotides -678 and -216 of the SOCS3 
promoter were tested by bisulfite sequencing. We found that methylation was not increased in 
SOCS3 promoter CpG island of any LGLL patient with respect to controls.  
 
Figure 21: (A) Methylation specific PCR of SOCS3 promoter in LGLs and the autologous LGL-depleted 





dinucleotides. The figure reports the methylation pattern in the promoter region of the SOCS3 gene for one 
representative control and two representative patients. The filled circles indicate methylated CpG dinucleotides, 
the empty circles unmethylated ones. The numbers indicate the CpG dinucleotide position before the start codon. 
The analysis of controls was performed in the sorted CTLs; instead in patients the analysis was performed on 
sorted LGLs. The methylation frequency, for each sequenced clone, was calculated as the number of methylated 
CpG dinucleotides over the total CpG dinucleotides present in the analyzed sequence. The difference of median 
methylation frequency methylation was similar in the patients with respect to the controls. 
6. MONONUCLEAR CELLS OF PATIENTS PRODUCED 
IL-6 AND THE SOLUBLE FORM OF IL-6-Rα 
Literature data report high IL-6 level in acute and chronic inflammatory conditions, where it 
activates cell survival and proliferation pathways53,54. With this as a background we studied 
IL-6 expression levels in T-LGLL patients and we observed by Elisa Test high quantity of the 
cytokine in patients’ plasma (Figure 22, 29.67 ± 8.91 pg/ml and 0.67 ± 1.37 pg/ml 
respectively, P<.05). 
 
Figure 22: Histograms of IL-6 level in plasma of patients and controls measured by ELISA test. 
Furthermore, we observed that patients' cells expressed higher mRNA level of IL-6 as 
compared to controls. This increased expression of IL-6 mRNA was restricted to the LGL-
depleted PBMC population (Figure 23 A, P<.01). Consistent results were obtained by ELISA 
test, analyzing IL-6 levels in the supernatants of cell culture after 24 hours incubation in 
RPMI 0.5% FCS medium.  
Patients’ PBMCs depleted of LGLs released high levels of IL-6 as compared to autologous 

















Figure 23: (A) IL-6 mRNA expression and (B) secretion level in patients (LGLs and LGL-depleted PBMCs, n = 
27) and in controls (CTLs and PBMC, n = 18). 
Recently, it has been found that IL-6 acts not only through the “classical signaling” but also 
by an alternative pathway called trans-signaling23. According to the classical signaling, IL-6 
first binds to the membrane IL-6 receptor alpha (mIL-6Rα), then the complex associates with 
the signal transducing membrane protein gp130. In the alternative signaling, IL-6 binds to the 
soluble agonistic form of IL-6Rα (sIL-6Rα) and can activate also cells lacking mIL-6Rα. 
Therefore, we analyzed IL-6Rα expression levels and by RT-PCR we found that IL-6Rα was 
poorly expressed by LGLs of patients as compared to PBMCs (mRNA arbitrary units: 3.76 ± 
1.44 vs 78.72 ± 28.33 respectively; P<.01) and to CTLs and PBMC from controls (mRNA 
arbitrary units: 73.57 ± 10.61 and 70.86 ± 10.85, respectively; P<.01 for each comparison) 
(Figure 24 A). 
By Elisa test we showed that the loss of IL-6Rα by leukemic LGLs is balanced by a 
significant higher level of sIL-6Rα in plasma of patients as compared with controls (Figure 24 
B: 84.32 ± 6.38 ng/ml and 51.22 ± 16.65 ng/ml, respectively; P<.05), suggesting that IL-6 


























































Figure 24: (A) Histograms of IL-6Rα mRNA expression level in patients (LGLs and PBMCs) and in controls 
(CTLs and PBMCs). (B) Histograms of IL-6Rα levels in plasma of patients and controls, measured by ELISA. 
7. IL-6 EXPRESSION IS INVERSELY CORRELATED TO 
THE AMOUNT OF CIRCULATING LGLs IN T-LGLL 
PATIENTS 
Due to the heterogeneity detected in the plasma levels of secreted IL-6, we tried to correlate 
the amount of IL-6 to the percentage of circulating LGLs in PBMCs (LGL range in our cohort 
of patients: 25%-95%).  
Interestingly, we observed that lower IL-6 levels were detected in patients presenting higher 
number of leukemic LGLs, on the contrary, patients with higher IL-6 levels associate to 
patients characterized by low circulating LGLs (Figure 25). 
The results indicate that IL-6 secretion was inversely correlated to LGL percentage. We 


























































characterized by high IL-6 plasma levels from patients with lower IL-6 levels. Considering 
that IL-6 is a mediator of inflammation, we suggest that low-burden disease patients are 
mostly characterized by an active inflammatory background. 
 
Figure 25: Histograms of IL-6 level in plasma of patients characterized by circulating LGLs < 55% and in 
plasma of patients with circulating LGLs > 55%, measured by ELISA. IL-6 levels in LGLs < 55% group: 24.61 
± 9.64 pg/ml; IL-6 levels in LGLs > 55% group: 2.05 ± 4.50 pg/ml; P<0.05. 
8. IL-6 IS INVOLVED IN SURVIVAL CELL 
MAINTENANCE AND IN STAT3 PHOSPHORYLATION 
STATUS 
As reported in Figure 26 A, freshly purified LGLs demonstrated a better survival when in 
culture with the residual autologous PBMCs or alone in the presence of exogenous IL-6 or 
with autologous plasma (10%). 
To evaluate whether LGL survival and STAT3 phosphorylation are dependent on IL-6 
released by patients’ PBMCs, these latters were incubated in the presence of blocking 
antibodies to IL-6 or IL-6Rα and both P-STAT3 and apoptosis level after 1, 2, 4 and 7 days of 
culture were analyzed. 
Our results indicated that LGL apoptosis statistically increased (Figure 26 B) with a 
concomitant P-STAT3 decrease (Figure 26 C) following incubation with anti-IL-6 or anti-IL-
6Rα. 
Moreover, we observed that the survival rescue obtained in LGL culture with autologous 


















autologous plasma IL-6 mediates LGL survival (Figure 26 D). These results suggest that IL-6 
is necessary to maintain STAT3 activation thereby supporting leukemic LGL survival. 
 
Figure 26: Apoptosis was measured after 1, 2, 4 and 7 days of culture in RPMI 0.5% FCS by Annexin V/PI. A 
staining with anti-CD57-FITC was used to identify leukemic LGLs from PBMCs. (A) Purified LGL apoptosis 
was analyzed in cells cultured alone or with autologous PBMCs or with IL-6 or with autologous plasma 10%. 
(B) LGL apoptosis time course and (C) WB analysis of P-STAT3 and STAT3 in PBMC at 4 hours of culture 
(two representative patients) with control IgG1, with anti-IL6 and anti- IL-6Rα Abs. β-Actin served as a loading 
control. (D) LGL apoptosis in culture alone and with autologous plasma in the presence of isotype control 
antibody and of anti-IL6 and anti-IL-6Rα Abs. The apoptosis histograms show the mean results (± SE) from 4 
individual experiments. 
9. IL-6 CAN BE PRODUCED BY MSCs AND MODULATE 
CCL5 EXPRESSION THROUGH STAT3 SIGNALING 
CASCADE 
Through STAT3, IL-6 activates the transcription of some target genes, among which CCL532. 
This cytokine, strongly expressed by PBMCs of T-LGLL patients31, is an important mediator 
of acute and chronic inflammation. Since IL-6/STAT3 axis is constitutively activated in T-
LGLL patients and CCL5 is over-expressed, we investigated whether IL-6/STAT3 axis could 






mRNA levels in T-LGLL patients, while in controls no significative increase has been 
detected (Figure 27). 
 
Figure 27: (A) CCL5 mRNA expression levels in patients’ LGLs and controls’ CTLs stimulated with IL-6 for 
one hour. Gene expression data are normalized to the expression levels of the housekeeping gene GAPDH. 
Moreover, by transwell migration assay, we detected a high motility of LGLs in presence of 
medium with CCL5, which in turn acts as a chemo-attractant in T-LGLL (Figure 28). 
 
Figure 28: Chemotaxis analysis for the evaluation of neoplastic LGL motility in presence/absence of CCL5 
stimulus for 24 hours. 
Being bone marrow mesenchymal stem cells (BM-MSCs) reported to be a source of IL-6, and 
considering that bone marrow has been frequently demonstrated to represent a privileged site 
of LGLs infiltration20, we investigated the role of BM-MSCs in CCL5 upregulation, 














































































By apoptosis analysis we found an increased survival of T-LGLs after incubation with MSCs’ 
medium, while treatment with IL-6 neutralizing antibodies decreased survival sustained by 
MSC conditioned medium (Figure 29). This result confirms the hypothesis that MSCs 
promote LGLs survival through IL-6 release.  
 
Figure 29: Apoptosis assay by Annexin V/PI on CTLs from controls and LGLs from patients. Results were 
obtained by cell cultures treated for 5 days with MSC medium in the presence of isotypic control, and with MSC 
medium added with anti-IL6 and anti-IL-6Rα Abs (in the histogram indicated with the general word “aIL-6”). 
By Transwell assay we evaluated the ability of neoplastic cells to migrate in presence of 
neoplastic MSC conditioned medium. We expressed results as Migration Index (MI= number 
of migrated cells in presence of MSC conditioned medium / number of migrated cells in 
presence of medium alone). 
 
Figure 30: Chemotaxis analysis for the evaluation of neoplastic LGL motility in presence/absence of MSC 
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We detected a high motility of LGLs in presence of MSC medium (Figure 30), therefore it 
could be hypothesized that MSCs, triggering CCL5 expression in LGLs through IL-6 release, 
could promote the recruitment of neoplastic cells in the bone marrow.  
10. IL-6 AND IL-6Rα EXPRESSION IS RESPONSIVE TO IL-
15 STIMULUS 
Considering the role of IL-15 in LGLL pathogenesis we evaluated IL-15 effect on IL-6 
signaling. By RT-PCR and Elisa Test we observed that IL-15 strongly induced IL-6 
expression and secretion in patients’ PBMCs after 24 hours culture (Figure 31 A and B, 
respectively).  
Figure 31: (A) IL-6 mRNA expression levels in patients and controls’ PBMCs in culture after 24 hours alone 
(mRNA arbitrary units: 5.073 ± 4.56 in patients’ PBMC and 1.47 ± 0.61 in PBMC from controls) and after 24 
hours with IL-15 (190.6 ± 127.56 in patients’ PBMC and 103.88 ± 21.01 in PBMC from controls. The increase 
of IL-6 expression after IL-15 stimulation is statistically significant (P<.01). Gene expression data are 
normalized to the expression levels of the housekeeping gene GAPDH. (B) Histograms of IL-6 level in cell 
culture supernatants of patients’ PBMC, measured by ELISA test (alone 24h condition: 20.91 ± 2.91 pg/ml; IL-
15 24h condition: 184.65 ± 67.69 pg/ml, P<.05). 
Moreover, by RT-PCR we observed that IL-15 can inhibit IL-6Rα expression in LGLs (Figure 
32). Therefore this cytokine could account for the down-expression of IL-6Rα observed in 
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Figure 32: Hystograms of IL-6Rα mRNA expression level in patients’ LGLs in culture after 24 hours alone 
(mRNA arbitrary units: 14.83 ± 5.8) and after 24 hours with IL-15 (2.91 ± 3.7). Gene expression data are 
normalized to the expression levels of the housekeeping gene GAPDH. 
11. BOTH IL-6 AND IL-15 PROMOTE LGLs SURVIVAL 
IL-6 is the main activator of STAT3 and IL-15 seems to promote IL-6 trans-signaling 
pathway in T-LGLL. Therefore, next step was the analysis of IL-6 and IL-15 effects on 
STAT3 activation in leukemic LGLs.  
By Western Blot analysis we observed that both 1 hour IL-6 stimulus and 24 hours IL-15 
stimulus strongly increased STAT3 phosphorylation levels (Figure 33 A-B), indicating that 
STAT3 protein in LGLs is responsive to these cytokines. 
These mechanisms therefore contribute to LGLs survival. 
 
 
Figure 33: WB analysis of P-STAT3 and STAT3 in patients’ LGLs at (A) 1 hours stimulus with IL-6 and at (B) 







































12. PATIENTS WITH A HIGH PERCENTAGE OF 
CIRCULATING LGLS MAY SHOW MISSENSE MUTATION 
IN STAT3 SH2 DOMAIN 
Recently, it has been discovered that mutational hot spots in the SH2 domain of STAT3 are 
present in a percentage of patients with T-LGLL41,42. Y640F and D661Y are reported to be 
the more frequent mutations (90% of cases) (Figure 35 A). Consistently, in our cohort of 
patients, by Sanger sequencing and PCR ARMS we also found only these mutations. We 
found 11 mutated out of 60 patients affected by T-LGLL (18%).  
12.1 MUTATIONAL ANALYSIS BY SANGER SEQUENCING 
Sixty T-LGLL patients were analyzed by Sanger Sequencing for their LGL and LGL-depleted 
PBMC population and mutations were reported in 9 patients (15%): 6 patients showed Y640F 
mutation and 3 patients showed D661Y mutation. Interestingly, when a patient is mutated, the 
mutation is found only in LGLs and not in remaining PBMCs. Moreover, we observed that:  
- not all LGLs are mutated at the same time, but STAT3 mutations can be found only in 
a subpopulation of LGLs; 
- in all the 17 healthy controls analyzed CTLs and PBMCs resulted unmutated in 
STAT3; 
- mutations were found only in patients with a high percentage of circulating LGLs. 
Considering the arbitrary cut off point proposed for IL-6 expression levels, mutations 
were found only inside the group of patients characterized by circulating LGLs >55% 
and low IL-6 level.  
12.2 MUTATIONAL ANALYSIS BY ARMS-PCR 
In order to confirm the results obtained by Sanger Sequencing, we performed also ARMS-
PCR method, which allows the identification of sequencing refractory mutations, for the 
detection of D661Y and Y640F mutations. 
Out of 60 T-LGLL patients analyzed 11 resulted mutated (18%): 8 patients showed Y640F 
mutation and 3 patients were characterized by D661Y mutation.  
Among these 11 patients, 9 were already found mutated by Sanger Sequencing. ARMS-PCR 
method therefore added 2 new mutated cases to our analysis. 
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12.3 PHENOTYPE OF LGL CLONE IN MUTATED PATIENTS 
Immunophenotype analysis showed a high heterogeneity in the group of patients (table 6). 
Among T-LGLL patients, the majority of cases displayed a double positive CD3/CD8 
leukemic clone and a low percentage of cases displayed a double positive CD4/CD8 or were 
CD4+/CD8- T clone.  
In the majority of cases, the leukemic clone is characterized by the expression of CD57. Only 
a subpopulation of LGLs expressed CD16, which can be coexpressed or not with CD57. 
Inside leukemic T cell population some cases showed the expression restriction for one or 
more (2-3) Vβ at the same time. 
By observing the phenotype of mutated as compared to the unmutated patients, we showed 
that STAT3 mutation not only identifies patients with >55% of PBMCs but is associated with 
a specific phenotype: 
- CD3/CD8 positivity 
- CD57 positivity 
- CD16 positivity 
- CD56 negativity 
Differently, patients with an LGL percentage >55% but negative for the mutation are 












Table 7: T-LGLL patients characterized by a percentage of circulating LGLs >55% on total PBMCs. 
 
Patients’ immunophenotypes, Vβ and KIR restriction and the results of mutational analysis by Sanger 




# Pt. DISEASE AGE/SEX % LGL IMMUNOPHENOTYPE Vβ / KIR MUTATION
1 T-LGLL M74 85% CD3/CD57/CD16 Vβ5.2 Y640F
2 T-LGLL M41 71% CD3/CD57/CD16 - Y640F
3 T-LGLL F62 55% CD3/CD57/CD16 Vβ2 D661Y
4 T-LGLL F73 62% CD3/CD57/16 Vβ7.1 Y640F
5 T-LGLL F76 73% CD3/CD57/CD16 Vβ21 Y640F
6 T-LGLL M52 89% CD3/CD57/CD16 KIR2D2/3 Y640F
7 T-LGLL M53 86% CD3/CD57/CD16 KIR2D2/3 Y640F
8 T-LGLL M54 72% CD3/CD57/CD16 - Y640F
9 T-LGLL F65 57% CD3/CD16 Vβ14 Y640F
10 T-LGLL F53 67% CD3/CD57/CD16 Vβ9KIR2D2/3 D661Y
11 T-LGLL F51 55% CD3/CD16/CD57 Vβ14 D661Y
12 T-LGLL F78 65% CD3/CD57/CD16 - -
13 T-LGLL M48 70% CD3/CD57/CD56 Vβ5.1 -
14 T-LGLL F73 65% CD3/CD57/CD56 - -
15 T-LGLL M85 78% CD3/CD57/CD56 Vβ13.6 -
16 T-LGLL M66 73% CD3/CD57/CD56 Vβ1 -
20 T-LGLL M40 95% CD3/γδ/CD56/CD16 KIR2D2/3 -
21 T-LGLL F73 66% CD3/CD57/CD56 Vβ2 -
22 T-LGLL F75 79% CD3/CD57/CD16 - -







In this PhD project, we provide evidence that two different mechanisms account for the 
constitutive STAT3 activation in patients with T-LGLL: 1) the high production of IL-6, 
released by autologous LGL-depleted population of patients' PBMC, and in the bone marrow 
MSCs, and 2) the down modulation of SOCS3, which is responsible for the lack of the 
physiological negative feedback mechanism controlling STAT3 activation. Interestingly, we 
demonstrated that in leukemic LGLs the constitutive activation of STAT3 may be down-
modulated by DAC, suggesting a putative role of demethylating agents in LGLL treatment 
strategies. Moreover, we demonstrated that the subset of patients characterized by STAT3 
mutations were specifically included within the high LGL burden patients' group, which 
seems to be independent by cytokine stimulation. 
The constitutive activation of JAK/STAT pathway has been claimed to be involved in the 
development of several human cancers, including hematologic neoplasms (acute myeloid 
leukemias, Sezary syndrome, multiple myeloma)40,55,56. In T-LGLL, Epling-Burnette et al 
reported that LGLs from patients constitutively express high levels of activated STAT3 as 
compared to PBMC of healthy individuals37. They also showed that STAT3 activation 
contributes to Fas resistance resulting in abnormal survival of leukemic LGL and is also 
responsible of the over-expression of the anti-apoptotic protein Mcl-137.  
During this PhD, we confirmed that over-expression and activation of STAT3 in T-LGLL is a 
common feature for all T-LGLL patients and demonstrated that patients’ PBMCs release high 
amounts of IL-6 as compared to healthy individuals, suggesting that the activation of STAT3 
may result from a persistent stimulation of this cytokine, which is central in inflammatory 
processes and has been demonstrated to play a role in multiple myeloma and in other 
neoplastic disorders where the JAK/STAT pathway is involved40,57,58. 
Furthermore, we provided evidence that IL-6 is secreted through a paracrine mechanism, 
since its production is not mediated by leukemic LGLs but by the residual normal autologous 
LGL-depleted PBMCs, likely cells belonging to the monocyte/macrophage lineage. Also 
MSCs seem to play a key role in the cytokine secretion in the bone marrow where patients’ 
LGLs show high frequency of infiltration20. Through the release of IL-6, our results indicate 
that MSCs are able to stimulate CCL5 secretion by LGLs, triggering the chemotactic 
environment of the bone marrow, since we demontrated the ability of CCL5 to induce the 
migration of T LGLs. 
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Taken together, these data highlight the importance of tumor environment59 and point out that 
additional cells, different from the malignant LGL clone, contribute to the disease 
development and maintenance. 
We also provided evidence that patients’ PBMCs release in vivo high amount of soluble IL-
6Rα allowing LGLs, that not express membrane-bound IL-6Rα but only gp130, to be 
responsive to IL-6 through the trans-signaling process60. This mechanism has been 
demonstrated in many chronic inflammatory diseases, including chronic inflammatory bowel 
disease, peritonitis, rheumatoid arthritis, asthma, as well as colon cancer, where IL-6 trans-
signaling is critically involved in the maintenance of a disease state, by promoting transition 
from acute to chronic inflammation60-62. Our results also indicate that IL-15, a well described 
cytokine crucial in LGLL pathogenesis, can sustain IL-6 trans-signaling, then contributing to 
maintain the inflammatory background of the disease. 
Both IL-6 and IL-15 stimuli strongly enhance the phosphorylation of STAT3, confirming 
their central role in maintaining LGL survival in LGLL, demonstrated also by the relevant 
inhibition of STAT3 phosphorylation in the presence of antibodies against IL-6 or IL-6Rα. 
Interestingly, even if STAT3 is constitutively expressed and activated in T-LGLL, we found a 
very low expression of its specific inhibitor, SOCS3, in patients’ LGLs as compared to the 
CTLs of controls. Consistently, the feedback loop sustained by this protein which is crucial in 
controlling the level of STAT3 activation, can be inhibited in some tumors characterized by 
P-STAT3 over-expression47,48,52.  
Comparison between pathological LGLs and the remaining autologous PBMCs indicate that 
the signaling pattern defined by high P-STAT3 and low SOCS3 expression was a discrete 
characteristic of leukemic LGLs. This mechanism in the pathophysiology of T-LGLL lacks a 
clear explanation yet. In fact, sequencing the entire coding region of 27 patients, we ruled out 
the presence of SOCS3 gene mutations, and also showed that the promoter was not 
inactivated via CpG island methylation, as demonstrated in other neoplastic clinical 
conditions47,48,52. 
Even if SOCS3 promoter in T-LGLL patients showed no methylation, by treating leukemic 
LGLs with the demethylating agent DAC, SOCS3 expression was restored, with reappearance 
of P-STAT3 suppression and inhibition of downstream signals, in particular Mcl-1 
expression63. Although the fine mechanisms tuning out SOCS3 expression has not up to now 
clarified, for the first time our results demonstrated a link between constitutive STAT3 
activation, ultimately resulting in LGL survival, and epigenetic regulatory mechanisms. More 
interestingly, our data provided evidence of the reversibility of epigenetic inhibition using 
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hypomethylating agents, thus opening the possibility that an epigenetic approach to re-express 
SOCS3 may be exploited for the treatment of T-LGLL64. 
Recently, recurrent somatic missense mutations (more often Y640F and D661Y) in the SH2 
domain of STAT3 have been reported in nearly one third of patients affected by LGL 
disorders41. It has been hypothesized that STAT3 mutations can enhance its constitutive 
activation by an increased stabilization of STAT3 homodimers or heterodimers through 
enhanced hydrophobic attraction between STAT monomers. However, this putative role of 
STAT3 mutations is still controversial. As a matter of fact, whereas STAT3 activation is a 
constitutive mechanism in all T-LGLL patients37,41, STAT3 mutations are reported only in a 
fraction of cases, despite that the presence of monoclonal rearrangement of TCR was shown 
in all patients41,42.  
In our series of patients we found 11 cases with STAT3 mutations (6 with Y640F and 2 with 
D661Y, 18%) out of 60 monoclonal patients analyzed. Interestingly, we demonstrated that the 
group of patients accounting for STAT3 mutations in T-LGLL is characterized by cases with 
high percentage of circulating LGLs (more than 55% LGLs)41,42, and it is worth of notice that 
previously published results about STAT3 mutations considered only patients with very high 
LGL clonal expansions. To compare our results with literature data by taking into account 
only patients with clonal and >55% LGLs, we found an incidence of mutations (11 out 29 
cases, 38%) more consistent with literature data. 
The finding that mutated patients affected by T-LGLL show a particular and distinctive 
phenotype of LGL clone (CD8+/CD57+/CD16+) further suggests that patients bearing 
STAT3 mutations might be distinguished as a different subgroup of patients. 
Another interesting feature of STAT3 mutated patients was that they were characterized by a 
very low level of IL-6 in their plasma. These results suggest that an initial step along the 
development of disease still characterized by low lymphocytosis (LGLs <55% of total 
PBMCs), is mostly sustained by extrinsic factors contributing to the relevant inflammatory 
background. A subsequent step can be recognized by a high lymphocytosis (LGLs >55% of 
total PBMCs) in which LGL disease likely goes on independently from exogenous stimuli, 
becoming self-maintaining due to the contribution of the emerging STAT3 mutations. It is 
suggested that these phases can represent two sequential steps in the progression of disease. 
Taking together, these results indicate that genomic mutations might only marginally account 
for in vivo activation of STAT3 in LGLL patients and further emphasize the heterogeneity of 
mechanisms sustaining LGLL. Among these the tumor environment play a key role, being 
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responsible for the activation of LGLs by antigene presentation, and for progression of the 
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